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ABSTRACT OF THE DISSERTATION
Analysis of Structural Variation and mtDNA Copy Number in Finns
by
Liron Ganel
Doctor of Philosophy in Biology and Biomedical Sciences
Computational and Systems Biology
Washington University in St. Louis, 2021
Professor Ira McCarthy Hall, Chair
Professor Nathan Oliver Stitziel, Co-Chair
Cardiovascular disease (CVD) is a complex disease responsible for more deaths
worldwide than any other cause according to the World Health Organization. Genetic association
studies for CVD and related risk factors have successfully identified hundreds of loci associated
with these complex diseases and traits, although much of their heritability remains unexplained.
Structural variants (SVs) - including insertions, deletions, duplications, and inversions - are an
understudied class of genomic variation that have the potential to explain much of the missing
heritability of CVD and other complex traits. Here, we discuss advances emerging from the
study of SVs in the context of CVD genetics using Finnish genomes.
Variant interpretation is an important step both in clinical sequencing pipelines and rare
variant association studies of the genetics of complex traits such as CVD. However, due to the
difficulty in detection and genotyping of SVs as well as the broad diversity of SV types, there
has been a scarcity of methods for interpreting these variants relative to those available for point
mutations. Here, we describe SVScore, a novel method for SV impact prediction by aggregating
existing genome-wide scores while incorporating SV type and transcript annotations. Using
xi

allele frequency in Finns as a proxy for pathogenicity, we show SVScore’s efficacy and uncover
interesting signatures of selection among SVs.
Furthermore, a genome-wide association study of SVs by another member of our group
led to the observation of a strong association between mitochondrial DNA copy number (MTCN) and several cardiometabolic risk factors for CVD. We identify several nuclear genomic loci
associated with MT-CN and use a modified Mendelian randomization framework to provide
evidence for a causal role for MT-CN in determining serum insulin levels. We further leverage
UK Biobank data to replicate the association between MT-CN and cardiometabolic traits in an
independent data set and show that adjusting for blood cell counts largely eliminates this signal.
In summary, our work suggests that MT-CN is in large part a proxy for blood cell counts, and
thus inflammatory status, in its association with metabolic traits.

xii

“Ok, well, sometimes science is more art than science, Morty. A lot of people don’t get that.”
- Rick Sanchez

“The story so far:
In the beginning the Universe was created.
This has made a lot of people very angry and been widely regarded as a bad move.”
- Douglas Adams
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Chapter 1: Introduction
1.1 Cardiovascular Disease and the Metabolic Syndrome
Cardiovascular disease (CVD) is a category comprising many diseases of the circulatory system,
including coronary heart disease (CHD), heart failure, stroke, and hypertension, but not
congenital heart conditions1. CVD was the leading cause of mortality both in the United States
and around the world in every year between 2007 and 2017, and thus represents a major global
health and economic burden1,2. In 2017, per 100,000 Americans, CVD was responsible for 165.0
deaths after adjusting for age, accounting for the largest proportion of the 731.9 age-adjusted
deaths3. This pattern holds true globally as well, as over 957,000 of the nearly 2,950,000 deaths
in 2019 were attributed to CVD, a larger proportion than any other cause of death2.
Metabolic syndrome (metS) is a related condition with high prevalence in the United
States. metS refers to several related disorders, including hypertension, dyslipidemia, obesity,
insulin resistance, and prothrombotic and proinflammatory states4. Individuals with metS have
approximately twofold risk of being diagnosed with CVD over five to ten years and fivefold risk
of being diagnosed with type 2 diabetes mellitus5. Among American adults from 2007 to 2014,
the age-adjusted weighted prevalence of metS was 34.3% (0.8% SE), with little variation across
sexes (35.3% in males and 33.3% in females)1,6. However, there was substantial variation in
metS prevalence with respect to age, with 54.9% (1.7% SE) of Americans over age 60 meeting
the criteria1,6.
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1.2 Genetics of CVD and metS
Much work has been carried out to quantify the genetic and environmental components of both
CVD and metS and implicate specific genetic loci in these disorders. Prior studies have found
CVD to be highly heritable, with estimated heritability values of 40-50% for CHD, 34-67% for
blood pressure, 26% for heart failure, and 34-42% for stroke7–10. Similarly, metS has been shown
to have a strong heritable component, with heritability estimates of 66% for low-density
lipoprotein cholesterol (LDL), 69% for high-density lipoprotein cholesterol (HDL), 58% for
triglycerides, and 70-80% for body mass index (BMI)11,12.
While genome-wide association studies (GWAS) have identified hundreds of loci
associated with these disorders, including over 250 for lipid traits, 150 for CHD, 100 for blood
pressure, and 30 for stroke8,13–15, the heritability of most of these complex phenotypes is not fully
explained by the variants with known associations. For example, known common variants only
explain approximately 38% and 10-20% of the heritability of CHD and serum lipid traits,
respectively8,16,17. This discrepancy, called “missing heritability”, is a longstanding problem in
human genetics common to most complex traits18,19. Numerous hypotheses have been proposed
to explain this issue, including difficult-to-detect interactions (such as epistasis and gene-byenvironment), lack of statistical power due to sample size limitations, and overestimation of total
heritability20–23.
One of the most compelling hypotheses posits that causal variants contributing to the
heritability of complex phenotypes such as metS and CVD have simply not been measured
(either by direct genotyping or indirectly through linkage disequilibrium). Much early traitmapping work was performed using genotyping arrays, meaning that rare variants were
necessarily excluded from these studies; the view that causal variants for complex traits are
3

largely rare is known as the common disease, rare variant (CDRV) hypothesis24–26. Differently
stated, the CDRV hypothesis claims that the genetic architecture of complex traits is
characterized by much allelic and/or locus heterogeneity, but that these rare variants may have
fairly high penetrances26. Linkage evidence points to significant locus heterogeneity in most
common disease, providing support for the CDRV hypothesis27. The proliferation of large whole
exome sequencing (WES) studies and those imputing lower-frequency variants has not solved
the missing heritability question, suggesting that if the CDRV hypothesis is correct, the truly
causal alleles are not detectable by WES, i.e. they must not all be small, coding variants 14,16.
The causal variants may be extremely rare alleles in noncoding regions of the genome or
they may be variants of classes not easily measured by methods typically used thus far, e.g.
structural variants (SV). Whole genome sequencing (WGS), while able to detect these alleles,
has until recently been cost-prohibitive at the scale necessary to detect variants of all but the
strongest effect sizes. However, recent technological developments have reduced the costs
associated with this technique, making large WGS cohorts more feasible and allowing
researchers to search for trait-associated variants of these types.

1.3 Value of Finnish Data for Trait-Mapping Studies
Genetic data from Finland are frequently used for studies seeking to map traits in the human
genome. One reason for this is the country’s extensive maintenance of birth, historical, and
electronic health records28. At least as valuable, however, are the country’s unique population
history and genetic isolation, which together make Finnish genetic data extremely useful for
studies aimed at mapping traits29, especially for identifying rare, highly penetrant variants of all
classes.
4

Finnish population history is characterized by a series of founder and bottleneck effects,
which tend to cause the proliferation of some rare alleles28,30. The Finnish founder population is
estimated to have contained a few thousand individuals who migrated mostly from the south
approximately 11,000 years ago28. Population in the Early Settlement Region, comprising the
southern and western areas of Finland, became more dense and permanent around 4,000 years
ago28. In the 16th century, small families began moving into the area termed the Late Settlement
Region, consisting of the northern and eastern reaches of the country, resulting in further
population bottlenecks28,30. This history, in combination with several extinctions and recolonizations in the last 2,000 years, rapid population expansion, and reproductive isolation, has
resulted in several unique features of modern Finnish genetics28,29,31.
One of these aspects is the relative homogeneity of the Finnish population, maintained by
its isolation, which makes it a prime region of interest for trait mapping studies 29,30. More
interesting for the purposes of identifying rare variation described above, however, is the
enrichment of deleterious alleles that are extremely rare or absent in non-Finnish Europeans32.
This results from the fact that some of these founder and bottleneck events are quite recent,
meaning these harmful variants have not yet been removed from the Finnish population by
purifying selection. Thus, it is much more feasible to detect trait associations with these variants
in Finns, as they may be too rare to test in the non-Finnish European population without
unfeasibly large sample sizes.
The enrichment of deleterious alleles has led to the Finnish Disease Heritage, a set of 36
rare, Mendelian diseases that are more common in the country, especially in the eastern regions
more affected by population bottlenecks30,33,34. However, as previously discussed, rare,

5

deleterious alleles may also have an impact on complex traits such as CVD and metS. As a
result, Finnish genetic data present a valuable opportunity to study rare, deleterious variation that
may contribute to the heritability of these complex phenotypes.

1.4 Description of Data in the Present Study
The present study utilizes three types of Finnish genotype data acquired in conjunction with the
FinMetSeq Consortium. These data came primarily from two cohorts: METSIM 35 and
FINRISK36, both of which are population cohorts with subjects chosen randomly, i.e. not
ascertained for any trait. METSIM samples were collected from men between 2005 and 2010 in
the Eastern Finnish city of Kuopio, resulting in a quite homogeneous cohort. Conversely,
FINRISK samples came from men and women in four separate health surveys over 15 years (in
1992, 1997, 2002, and 2007) conducted in multiple regions of Finland. The relative homogeneity
of METSIM is one of the reasons some of the interpretation in Chapter 3 is limited to results
obtained from this cohort. Both METSIM and FINRISK had rich phenotype data paired with the
genetic samples. In total, 137 phenotypes were available, comprising primarily glycemic,
anthropomorphic, and lipid traits as well as several disease endpoints. The phenotype values
used in the current work are the post-processing values from an earlier FinMetSeq Consortium
study by Locke et al.37; the latter study performed several phenotype transformations that are
described in that manuscript. The sample sizes of each cohort are shown in Table 1.1.
Genotyping array data for 17,718 samples (9,791 METSIM and 7,927 FINRISK) were
acquired from previous studies of these cohorts38,39. As part of the Locke et al. study, these
array-based genotypes were imputed using the Haplotype Reference Consortium panel v1.1 with
the Michigan Imputation Server40,41. WES was also performed by Locke et al. on 19,034 samples
6

(9,813 METSIM and 9,221 FINRISK)37. Both array-based and WES genotypes are utilized in
Chapter 3.
Finnish WGS data generated at the McDonnell Genome Institute are used in Chapters 2
and 3, but the sample sizes are different between the Chapters. The work described in Chapter 2
uses WGS data from 1,355 samples, as these are all of the samples for which WGS had been
completed at that time. This set includes 476 METSIM and 480 FINRISK samples, as well as
396 samples from Finnish familial dyslipidemia cohort EUFAM42, 2 hydatidiform moles, and the
publicly available genome NA12878. The data analyzed in Chapter 3 consist of only METSIM
and FINRISK due to the availability of phenotype data in these cohorts. However, by the time
the work in Chapter 3 was performed, WGS had been completed in 4,163 (3,074 METSIM and
1,089 FINRISK).
Another source of data utilized in Chapter 3 is from the UK Biobank
(https://www.ukbiobank.ac.uk/). This resource contains data from approximately half a million
individuals living in the United Kingdom that researchers can apply to access. Participants are
subjected to a wide array of genetic measurements, including array-based genotyping of 800,000
variants and imputation of 90 million variants in addition to WES of some samples and, in the
future, WGS. Furthermore, they answer extensive lifestyle questionnaires, provide health
information and anthropometric measurements, and donate samples that are subjected to
biochemical assays. Some individuals are also imaged using magnetic resonance imaging. At the
time of the work described in Chapter 3, most of the phenotype information was available for
virtually all participants, as was imputed genotyping array data. Furthermore, WES data from
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approximately 50,000 individuals was available; this was also analyzed in the work detailed in
Chapter 3.

1.5 Summary of Aims and Motivation
This work consists of two main aims, described in Chapters 2 and 3, respectively. Aim 2 is split
into three sub-aims, as shown below:
❏ Aim 1 (Chapter 2): Develop, implement, and evaluate a method for in silico
prediction of structural variant pathogenicity
❏ Aim 2 (Chapter 3): Interrogate the genetics of peripheral blood mitochondrial DNA
copy number (MT-CN) and its relationship to metabolic syndrome
❏ Aim 2a: Investigate the germline genetic determinants of peripheral blood
MT-CN in Finns
❏ Aim 2b: Assess the evidence for a causal relationship between MT-CN and
fasting serum insulin in Finns
❏ Aim 2c: Utilize UK Biobank data to replicate and interpret the association
between MT-CN and metabolic syndrome
On first glance, Aims 1 and 2 may seem somewhat disparate. It is true that that Aim 1
largely focuses on methodology and Aim 2 is more data-driven, although Aim 2b does have a
significant methodological component. However, both of these projects arose from the same
broader effort to leverage WGS data to incorporate SVs - particularly rare SVs - into complex
trait association studies.
Aim 1 was motivated by the desire to incorporate SVs into rare variant association
studies (RVAS) in order to implicate novel genes in the genetics of complex traits such as metS
8

and CVD. This is nontrivial because while an important step in any RVAS is the filtering of
variants to enrich for functional alleles (see Section 2.2), few impact prediction methods existed
for SV before the work described in Chapter 2. Furthermore, those that did exist did not
adequately treat this highly diverse class of large variants.
Similarly, Aim 2 was motivated by an incidental finding in an actual genome-wide SV
trait association study performed by Lei Chen, a member of our research group. As described in
Chapter 3, this finding initially manifested as an apparent association between several SVs and
metS-related traits, particularly fasting serum insulin levels and fat mass. Further investigation
by Lei revealed that the underlying association was between metS and MT-CN, not SV. As is
frequently the case in scientific inquiry, the focus of our efforts then shifted in a direction
dictated by the data, i.e. toward MT-CN instead of SV. Still, the motivation of both of these
Aims was rooted in the assessment of the contribution of SV to complex traits. As such, it is
appropriate to include both Aims in the present work despite a non-negligible divergence in
subject matter, especially in light of the genetic nature of the analyses in Aim 2.

9

1.6 Figures and Tables
Table 1.1 Sample sizes divided by cohort.
Aim

Assay

METSIM

FINRISK

Other

Total

1

WGS

476

480

399

1355

WGS

3074

1089

0

4163

WES

9813

9221

0

19034

Imputed array

9791

7927

0

17718

2
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Chapter 2: Aim 1 – an in silico Pathogenicity
Prediction Method for Structural Variants
2.1 Introduction to Structural Variation
Structural variants (SVs) are a broad class of genomic rearrangements often defined as variants
greater than 50 bp in length43. This includes copy number variants, such as insertions, deletions,
tandem duplications, and interspersed duplications, as well as copy number neutral
rearrangements, such as inversions and translocations (Figure 2.1). Other complex
rearrangements are also possible, which may, but do not necessarily, involve changes in copy
number. Although short-read sequencing, e.g. Illumina sequencing, is the current gold standard
in genomics, this technology can prove problematic for detection and genotyping of SVs as the
variant length is often much longer than the read length. For example, the most recent Illumina
sequencer, the Novaseq 6000, can output reads of up to 250 base pairs (bp) in length, while some
SVs can be over 10 Mb in length44. This is not the case for single nucleotide polymorphisms
(SNPs) or small insertions and deletions (indels); as a result, SVs have historically been
understudied relative to these other classes of genetic variation.
Nevertheless, there is evidence that SVs contribute significantly to human phenotypes.
Despite there only being up to 10,000 SVs in the average genome45 as compared to 4-5 million
SNPs and small indels44, SVs are thought to affect more bases on average44, giving them
significant potential for phenotypic consequences.. Furthermore, SVs are likely responsible for a
disproportionately large fraction of expression quantitative trait loci relative to SNPs44,46,
11

providing a possible mechanism for the phenotypic impact of SVs. In fact, there are numerous
examples of SVs implicated in diseases such as Crohn’s disease, rheumatoid arthritis, diabetes,
autism, and schizophrenia47–49.

2.2 Pathogenicity Prediction
Pathogenicity prediction is a crucial component of many sequencing pipelines. For example, in
clinical sequencing of rare disease cases, pathogenicity prediction of detected variants must be
used in order to distinguish clearly benign alleles from potentially disease-causing ones50. This
step is crucial because by definition, rare diseases have a small number of cases, leading to
insufficient power to make statistical inferences about any individual variant of interest. In the
case of ultra-rare diseases, there may only be one case to sequence, leading to the so-called “N of
1” problem51. As a result, biological knowledge must be incorporated in order to identify
putatively pathogenic alleles50.
Another application of pathogenicity prediction is for RVAS of complex traits or
common diseases. In order to achieve sufficient statistical power to make an inference about a
rare polymorphism, sample sizes must often be impractically large. Furthermore, not only do
large cohort studies detect large numbers of rare variants, leading to a significant multiple testing
burden, some variants are invariably present only in a single sample, recapitulating the “N of 1”
problem. In the sequencing era, some studies have avoided these problems by aggregating rare
variants into units of interest, e.g. genes or pathways. This allows for joint testing of all rare
alleles in a gene or pathway against a phenotype. The two main classes of statistical tests for
RVAS are burden and variance-component tests. Burden tests evaluate phenotypic similarity
among samples with a variant in a given gene relative to samples without52,53. Meanwhile,
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variance-component tests examine whether the genetic effects have a variance different from
zero52. Burden tests are particularly sensitive to the inclusion of phenotypically neutral variants,
although they outperform variance-component tests when all included variants affect the gene in
the same direction (e.g. all alleles cause a loss of gene function)53. As a result, RVAS
performance is maximized when filtering variants to enrich for truly functional alleles, creating a
need for powerful pathogenicity prediction methods.
SNPs benefit from the existence of population reference databases such as dbSNP 54 and
gnomAD55 that are useful for looking up variants of interest. These databases are invaluable, as
high allele frequency is a powerful exclusion criterion for a putatively pathogenic variant.
However, rare variants may still be benign. As allele frequency databases are not useful in
classifying these variants, in silico variant prioritization algorithms are necessary. Many such
methods exist for SNPs and even indels, including SIFT56, Polyphen-257, MutationTaster58,
LRT59, and VEP60. These methods generally consider inter-species conservation data and
genomic annotations to predict variant impact. In RVAS involving SNPs and indels, these
algorithms are often used in concert due to limited overlap between their predictions37,59,61.
In the past, impact prediction of SVs was not of great interest because detection and
genotyping methods for these variants were immature. More recently, advances from our group
and others have improved these pipelines62–64, necessitating robust methods of pathogenicity
assessment for these variants. However, prioritization of SVs is more difficult than the analogous
SNP problem for several reasons. For one, due to the reasons listed above, extensive population
databases have not historically been available to enable allele frequency lookup of these
polymorphisms. Furthermore, in silico prediction is complicated by the diversity of variant types
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and sizes as well as the uncertainty that often exists around the exact location of SV breakpoints,
even using modern detection methods. As a result, RVAS of complex traits have largely ignored
SV despite their potential to greatly impact these phenotypes.
Notably, since the publication of the work described in this Chapter, a few populationscale SV databases have been published, including one from our group45,65. However, as
previously described, these databases do not invalidate the need for an in silico algorithm to
predict SV impact because of the former’s inability to distinguish between benign and
deleterious rare variants.

2.3 SVScore
As described in Section 2.5.2, there were a few methods of prioritizing structural variants
before the work described later in this Chapter, but they were fairly rudimentary in several ways.
Specifically, they were not quantitative, they only worked for a subset of SV types, and none
adequately incorporated the considerations discussed in Section 2.2. However, an opportunity
arose to address this need with the publication of several single-nucleotide resolution
pathogenicity prediction methods including CADD66, fitCons67, and Eigen68. These algorithms
assign a score to each base in the reference genome, creating the possibility for an in silico
algorithm that quantifies an SV’s impact by aggregating these scores over the affected genomic
intervals. This method, which we called SVScore, is summarized here and described in detail in
Section 2.5.
The core of the SVScore algorithm is the aggregation of single-base pathogenicity scores
over a set of relevant intervals determined by an SV’s type and coordinates. The final score
assigned to a given SV is the maximum across all interval scores. Generally, the intervals chosen
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are the confidence intervals around each breakend and, for some SV types, the entire span of the
variant. In Section 2.5, the function used to aggregate scores was the mean of the top 10 scores in
the interval, although several other functions are supported by SVScore. This function was
chosen instead of a simple mean in order to sufficiently weight large SVs that span a small, highscoring locus. It is also preferable to a simple maximum because the latter would inflate the
scores of variants with large confidence intervals around the breakends simply because they are
imprecisely detected. Another feature of SVScore is the calculation of truncation scores in cases
where an SV appears to truncate a transcript, which allows for greater weight to be given to
gene-disrupting SVs. A final notable feature of SVScore is its consideration of probability
distributions over breakend confidence intervals. LUMPY62, an SV calling tool developed in our
group, outputs the probability distribution function (PDF) of the true breakpoint’s location over
the confidence interval around each breakend. SVScore accounts for this probability distribution
by weighting the score at each possible breakpoint by the value of the PDF at that position. This
allows for better pathogenicity prediction in cases where a PDF has a long tail, adding many
low-probability bases to the confidence interval.
SVScore has many advantages over prior SV prioritization methods. First, it provides a
quantitative pathogenicity score for a broad range of SV types that incorporates SV type, SV
length, and imprecision around breakpoint coordinates. It also has significant flexibility, with
several options for aggregation functions, the ability for the user to supply transcript annotations
to be used, and extensibility to any genomic scoring scheme. Finally, SVScore is an annotation
tool for files in Variant Call Format (VCF). As a result, SVScore’s output is a VCF that can
easily be used as input for further downstream analysis.
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2.4 My Role
The algorithm underlying SVScore described in Section 2.3 was developed by my mentor - Dr.
Ira Hall - and me. I performed the implementation, testing, benchmarking, and evaluation of the
software with some statistical support from Haley Abel. The SV callset was generated by Haley.
Abel, while the SNP callset used for comparison was generated by Dave Larson and Indraniel
Das. The samples were provided by the FinMetSeq consortium and sequenced at the McDonnell
Genome Institute.
What follows in Section 2.5 is a version of the SVScore manuscript, which was published
in abridged form in 2017 in the journal Bioinformatics69. I am the first author on this article.

2.5 SVScore: An Impact Prediction Tool For Structural
Variation
2.5.1 Abstract
Motivation: Structural variation (SV) is an important and diverse source of human genome
variation. Over the past several years, much progress has been made in the area of SV detection,
but predicting the functional impact of SVs discovered in whole genome sequencing (WGS)
studies remains extremely challenging. Accurate SV impact prediction is especially important for
WGS-based rare variant association studies and studies of rare disease.
Results: Here we present SVScore, a computational tool for in silico SV impact prediction.
SVScore aggregates existing per-base single nucleotide polymorphism pathogenicity scores
across relevant genomic intervals for each SV in a manner that considers variant type, gene
features, and uncertainty in breakpoint location. We show that in a Finnish cohort, the allele
frequency spectrum of SVs with high impact scores is strongly skewed toward lower
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frequencies, suggesting that these variants are under purifying selection. We further show that
SVScore identifies deleterious variants more effectively than naive alternative methods. Finally,
we demonstrate that high-scoring tandem duplications are under surprisingly strong selection
relative to high-scoring deletions, suggesting that duplications may be more deleterious than
previously thought. In conclusion, SVScore provides pathogenicity prediction for SVs that is
both informative and meaningful for understanding their functional role in disease.
Availability: SVScore is implemented in Perl and available freely at
http://www.github.com/lganel/SVScore for use under the MIT license.

2.5.2 Introduction
Structural variation (SV) is an important source of human genome variation that includes
deletions, duplications, inversions, mobile element insertions, translocations, and complex
rearrangements. Over the past several years, much progress has been made in the area of SV
detection, and we are now able to routinely detect 5,000-10,000 SVs in a typical deeply
sequenced human genome44. However, predicting the functional impact of SVs discovered in
whole genome sequencing (WGS) studies remains extremely challenging. Accurate SV impact
prediction is especially important for WGS-based rare variant association studies and WGSbased studies of rare disease.
There have been many efforts to predict the effects of single nucleotide polymorphisms
(SNPs), including SIFT56, PolyPhen57, and VEP60. More recent tools such as fitCons67, CADD66,
and Eigen68 precompute scores across the genome that predict the importance of each base in the
genome, often at the resolution of possible substitutions at each nucleotide.
Constructing similar methods for SV is difficult due to the diversity of variant size and
type. Variant type is important because, for example, a deletion spanning an entire gene is likely
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to have vastly different functional consequences than an inversion with the same coordinates.
Furthermore, current sequencing technologies make precise SV breakpoint detection difficult,
resulting in uncertainty about their exact location. SV impact prediction methods must take all of
these factors into consideration in order to robustly prioritize pathogenic variants.
There have been cursory attempts at SV impact prediction in the past. ANNOVAR 70
annotates previously-reported copy number variants (CNVs) and names overlapping genes, but
does not make pathogenicity predictions, nor does it handle balanced rearrangements. VEP
performs superficial consequence prediction for SVs, but only for a limited range of variant
types (insertions, deletions, and duplications). GECCO is a method that classifies CNVs into
“benign” and “pathogenic” bins, but does not work for copy-number neutral events such as
inversions71. Crucially, no existing method provides a quantitative SV pathogenicity score.

2.5.3 Methods
We present SVScore, a novel computational tool for in silico SV impact prediction. SVScore
depends on an existing set of per-base pathogenicity scores; we use the precomputed SNP scores
from CADD v1.3, although any other scoring scheme could potentially be used. For each SV in a
callset in Variant Call Format (VCF), SVScore aggregates these scores across a set of genomic
intervals determined by the variant type, affected gene features, and uncertainty in the location of
the breakpoints (Figure 2.2). To aggregate these scores into interval scores, SVScore first uses
tabix72 to extract the scores in the interval from a text file. If multiple scores are given for a
single locus (e.g. CADD provides scores for each possible substitution at a position), SVScore
uses the maximum score per position. It then applies an operation (e.g. max or sum; See
Operations) to each interval to summarize the per-base scores into interval scores. For each
operation, one score is computed per interval.
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Intervals
As shown in Figure 2.2A, a score is calculated for dosage-altering variants over the interval
between the most likely breakpoints (the boundaries of the SV-affected region), designated
SPAN. The chosen operation is applied to the base scores in this region to calculate the SPAN
score.
For all variants, scores are calculated across the confidence intervals (CIs) around the left
and right breakpoints of every supported variant type. As insertions have only one breakpoint,
the left and right CIs are the same. In these intervals (designated LEFT and RIGHT), the scores
aggregated are the possible breakpoint scores, which are defined as the average of the scores of
the 2 bases immediately flanking each possible breakpoint. If a breakpoint location is known
precisely, the interval score is reported directly as the possible breakpoint score regardless of the
operation.
Scores may also be calculated over truncation intervals, designated LTRUNC or
RTRUNC depending on which breakpoint is involved. Truncation scores reflect the ability of
certain SV types to truncate transcripts regardless of variant length (e.g. by disrupting an exon).
Truncation intervals extend from the truncating breakpoint to the furthest downstream base of
the affected transcript (Figure 2.2B). These scores are calculated for deletions, insertions,
inversions, and mobile element insertions that intersect one or more genes. Figure 2.2B shows
the logic for predicting whether an SV of one of the above types truncates a given transcript
based on breakend and exon coordinates. Any breakpoint of a truncating type whose CI overlaps
an exon is considered to truncate the transcript. Furthermore, a variant whose breakpoint CIs are
contained within two different introns is deemed truncating, as is a variant with one CI in an
intron and the other outside the transcript. Any variant whose breakpoint CIs are both completely
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contained within the same intron is not deemed truncating, so no truncation score is calculated.
SVScore uses vcfanno73 v0.0.11to find exons and introns that overlap SVs. As with SPAN
scores, truncation scores are calculated from individual base scores rather than possible
breakpoint scores.
Operations
The operations currently supported are: maximum, sum, mean, and mean of the top N scores. If
multiple operations are selected in a single run, SVScore will apply all of the operations to each
interval in parallel, assigning each SV a score for each operation-interval pair. The maximum of
all of a variant’s interval scores is reported as the score for the given operation and added to the
INFO column of the VCF line. The individual interval scores can be reported as well using a
command-line option.
SVScore supports weighting possible breakpoint scores using probability distributions
calculated by tools such as LUMPY62, as recorded in the INFO column. These give the
probability of the true breakpoint being located at each possible breakpoint in a CI. Weighting
the possible breakpoint scores using these distributions is important for two reasons. First, the
expected score scales with size for the maximum and sum operations, causing a bias toward
variants with large CIs. However, these variants are simply detected imprecisely, which is
unrelated to their true pathogenicity. The second reason is that bases at a tail of the breakpoint
probability distribution should not be given the same weight as those in the center of the
distribution, as the former bases are less likely to be truly affected. When probability
distributions are available, SVScore can incorporate them into the calculations of mean scores. If
they are not present, SVScore simply assumes a uniform distribution over the CI. For weighted
means of the top N bases in each interval, possible breakpoint scores are first weighted by the
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probability density function, then the top N are chosen and the probability density function over
the chosen bases is rescaled to sum to 1.
Probability distribution weighting is only available when using the overall mean or the
mean of the top N bases. Otherwise, weighting LEFT and RIGHT scores unfairly biases the
scores toward dosage altering variants. These variants have a SPAN score that is unweighted by
any probability distribution (as there is no probability distribution across a SPAN) and thus likely
to be greater than LEFT and RIGHT scores of balanced rearrangements. However, the weighted
mean of a breakpoint CI is similar in scale to the mean of a SPAN, making these comparisons
fair.
Size Distribution Matching
To compare the odds ratios for the deletions and tandem duplications within the top 10% of SVs
by impact score (Figure 2.3, “DEL” and “DUP”), we defined 49 logarithmically sized length
bins between 1 and 106 bp, and added a 50th bin for lengths greater than 106 bp. The edges of
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these bins were defined by bn, where b = √106 ≈ 1.326 and n = 0,1,2,…,49. We then placed
the deletions and duplications in the appropriate bins according to their lengths. Within each size
bin, we compared the number of deletions (x) and duplications (y) present, and sampled
min(x,y) variants without replacement from both the deletions and duplications in that bin. We
then aggregated all sampled deletions and all sampled duplications and calculated the odds ratio
for each using the bottom 50% of SVs as benign variants. This process was repeated 100,000
times, and the mean of the calculated odds ratios was reported for each variant type. The 95%
confidence intervals shown in Figure 2.3 were drawn from the 2.5th to the 97.5th percentile of the
odds ratio distribution.
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To compare the distributions of impact scores for known pathogenic variants from
ClinGen74 and 1,000 Genomes Phase 3 SVs44 or FinMetSeq SVs, a similar procedure was used
to adjust the size distributions. First, any variants with a score of 100 (meaning that the variant
length was greater than 1 Mb) were excluded, leaving 261 variants. These SVs were then binned
by size as before, and min(x,y) SVs were again sampled without replacement from both the
comparison data set (1,000 Genomes or FinMetSeq) and the ClinGen variants. In this case,
however, this sampling was repeated 1,000 times, and the sampled variants (totaling 258,000
from each) were aggregated.
SV Callset Generation
Cohort-level structural variant calls were produced using the SpeedSeq SV pipeline63, followed
by the svtools package75 v0.2.0. Briefly, speedseq sv, which comprises LUMPY for SV calling
based on discordant pairs and split-reads; svtyper63 for SV genotyping; and cnvnator76 for readdepth based CNV detection; was run on each sample individually. The individual-level calls
were sorted and merged using svtools lmerge, and then each sample was re-genotyped and copy
number annotated at all variant positions using svtools genotype and copynumber, and pasted
into a single cohort-level VCF. svtools classify was used to reclassify putative deletions and
duplications based on the read-depth information as well as to annotate calls overlapping known
LINE and SINE elements. Finally, inversion calls and unclassified novel adjacencies (i.e. BNDs)
were subjected to an additional filter: inversion calls in which fewer than 10% of reads supported
either breakpoint or in which either discordant pairs or split-reads represented less than 10% of
the evidence supporting the variant were excluded. Likewise for BNDs: calls where either
paired-end or split-read evidence comprised less than 25% of the evidence supporting a variant
were flagged as low quality.
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SNP Callset Generation
Data were aligned in aggregate using SpeedSeq's (gms branch - https://github.com/halllab/speedseq/tree/gms commit 1aa63c99b02d76db58db1182efe450b27f98e819) realign
command. Briefly, each individual lane or sub-lane was stored as an unaligned BAM file
containing read group information. For each possible library, SpeedSeq was used to convert each
BAM to interleaved FASTQ and align it by streaming through mbuffer (v20140302;
http://www.maier-komor.de/mbuffer.html), bwa mem77 (v0.7.10; -t 8 -C -p), samblaster78
(v0.1.22; --excludeDups --addMateTags --maxSplitCount 2 -minNonOverlap 20) and sambamba79 (v0.5.4) for BAM conversion (sambamba view) and
sorting (sambamba sort). Both discordant and split-read containing BAM files were stored
for later analysis by LUMPY. Python (v2.7) scripts that are part of SpeedSeq were utilized for
BAM to FASTQ conversion, header addition and read group addition.
Duplicates were marked by samblaster during alignment (but not included in the splitter
and discordant BAM files). In the case of multiple libraries, a single BAM file was created using
sambamba merge to merge the aligned BAMs from each individual library into a single file.
Variant calls were generated using GATK80 HaplotypeCaller (v3.4; -ERC GVCF -GQB
5 -GQB 20 -GQB 60 -variant_index_type LINEAR variant_index_parameter 128000) parallelized into 13 groups of chromosomes
empirically chosen to have approximately equal run times. Within each group of chromosomes,
each chromosome was run in serial.
GVCFs containing SNVs and Indels from GATK HaplotypeCaller were combined
(CombineGVCFs), genotyped (GenotypeGVCFs; -stand_call_conf 30 stand_emit_conf 0), variant score recalibrated (VariantRecalibrator) and filtered
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(ApplyRecalibration) using GATK (v3.4). SNP variant recalibration was performed using the
following options to VariantRecalibrator and all resources were drawn from the GATK resource
bundle (v2.5):
●

-mode SNP

●

-resource:hapmap,known=false,training=true,truth=true,prior=15.0

●

-resource:omni,known=false,training=true,truth=true,prior=12.0

●

-resource:1000G,known=false,training=true,truth=false,prior=10.0

●

-resource:dbsnp,known=true,training=false,truth=false,prior=2.0

●

-an QD -an DP -an FS -an MQRankSum -an ReadPosRankSum

●

-tranche 100.0 -tranche 99.9 -tranche 99.0 -tranche 90.0

Indel variant recalibration was performed using the following options to
VariantRecalibrator (with the same resource bundle as with SNPs):
●

-mode INDEL

●

-resource:mills,known=true,training=true,truth=true,prior=12.0

●

-an DP -an FS -an MQRankSum -an ReadPosRankSum

●

--maxGaussians 4

●

-tranche 100.0 -tranche 99.9 -tranche 99.0 -tranche 90.0

When applying the variant recalibration the following options were used:
●

For SNPs: --ts_filter_level 99.9

●

For Indels: --ts_filter_level 99.0

Subsequently, the resulting VCFs were processed to remove alternate alleles where the allele
count was 0 in the cohort (GATK SelectVariants –removeUnusedAlternates). The
remaining calls were then processed using vt81 (v0.5) to decompose multi-allelic variants (vt
decompose -s), normalize indel representations (vt normalize), and remove duplicate calls
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(vt uniq). After processing with vt, sites where >2% of samples were missing genotypes were
removed using a Python script. Sites previously discovered in the 1,000 Genomes Project phase
3 call set were annotated using bcftools72 (v1.2) annotate (-a
ALL.wgs.phase3_shapeit2_mvncall_integrated_v5.20130502.sites.dec
ompose.normalize.reheader.w_ids.vcf.gz –c ID) and gene annotation added
using the Ensembl Variant Effect Predictor (v76; --force_overwrite --offline -fork 12 --cache --dir_cache $VEP_CACHE --dir_plugins
$LOFTEE_PLUGIN --plugin
LoF,human_ancestor_fa:$LOFTEE_PLUGIN/human_ancestor.fa.gz,conser
vation_file:$LOFTEE_PLUGINphylocsf.sql --sift b --polyphen b -species homo_sapiens --symbol --numbers --biotype --total_length
-o STDOUT --format vcf --vcf --fields
Consequence,Codons,Amino_acids,Gene,SYMBOL,Feature,EXON,PolyPhen
,SIFT,Protein_position,BIOTYPE,LoF,LoF_filter,LoF_flags,LoF_info
--no_stats). Analysis was limited to SNPs with VQSLOD > 0.8150.

2.5.3 Results and Discussion
To evaluate SVScore’s computational performance, we computed scores for a set of high
confidence SVs called from WGS of 1,355 mostly Finnish WGS datasets (see Section 2.5.3).
Scores were calculated using SVScore v0.5.1 with 5 operations – maximum, sum, weighted
mean, and weighted mean of the top 10 and 100 bases in each interval. On a machine with two
Intel Xeon E5-2670 processors (each with 16 threads) and 128 GB RAM, the total CPU time was
341 minutes. With 21,426 SVs passing all of our filters (Figure 2.4), the average time per variant
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was 1.01 seconds (Table 2.1). The average memory used was 1.7 GB, and the maximum
memory was 3.5 GB.
To evaluate SVScore’s effectiveness in predicting deleterious variants, we used
population allele frequency as a proxy for pathogenicity. Due to the effects of purifying
selection, strongly pathogenic variants are likely to be observed at very low frequency in the
human population. Thus, if SVScore is an accurate predictor of pathogenicity, the variants it
predicts to be deleterious should be significantly rarer than those it predicts to be benign. For this
experiment, impact scores were calculated using the weighted mean of the top 10 bases in each
interval and exon/intron annotations from refGene. Figure 2.5 shows the allele frequency spectra
of “pathogenic” (impact scores at or above the 90th percentile), “benign” (below the 50th
percentile), and “intermediate” variants (all others). The pathogenic bin comprised 2 mobile
element insertions, 563 tandem duplications, 1,302 deletions, and 77 other novel adjacencies
(Figure 2.6; for this analysis, we excluded inversions, which made up only 0.56% of the total
variants detected). These predicted pathogenic variants were heavily skewed toward the rare (AF
< 0.01) end of the spectrum, while predicted benign variants were heavily skewed toward the
common (AF >= 0.05) end, and variants with intermediate scores were between the other two
categories (Figure 2.5). This suggests that high-scoring SVs are under strong purifying selection
relative to low-scoring SVs, which strongly supports the utility of our impact scoring strategy.
To quantify the strength of this effect, we computed odds ratios representing how much
more likely a pathogenic variant was to be rare in a population than a benign variant. We found
that pathogenic variants (with score at or above the 90th percentile) were significantly more
likely than benign variants (score below the 50th percentile) to be rare (< 1% allele frequency) as
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opposed to common (>= 5% allele frequency) in the population (OR = 13.06, p = 5.43×10-323,
Fisher’s Exact Test). We calculated this odds ratio for several other definitions of “pathogenic”
and “benign”, (Table 2.2, Figure 2.3). First, we tested several other SVScore percentile
thresholds, keeping the definition of benign as the bottom 50% of variants (SVScore Threshold
section of Figure 2.3). As the threshold was relaxed, the odds ratio generally decreased because
of the addition of lower-scoring variants into the “pathogenic” bin. The odds ratio of the top 1%
of impact scores was very high because at this threshold, there were 180 rare pathogenic SVs and
only 12 rare benign ones. Next, we compared this to several odds ratios calculated for high
confidence SNPs called on the same set of samples, using CADD v1.3 directly as the scoring
scheme (SNP CADD Threshold section of Figure 2.3). To achieve similar odds ratios, we tested
SNP thresholds that were much more stringent than the SV thresholds because the number of
SNPs detected was several orders of magnitude greater than the number of SVs detected. As with
SVs, SNP odds ratios trended downward as the pathogenicity threshold was relaxed.
We further studied the variants in the top 10% of impact scores according to SVScore
(Top 10% SVScores section of Figure 2.3; Figure 2.6). To compare SVScore’s effectiveness in
coding and noncoding regions, we calculated odds ratios for coding and noncoding SVs in this
subset, again defining benign by the bottom 50% of SV impact scores. All variants with at least
one breakpoint CI overlapping a refGene exon annotation were considered coding, and all others
were designated noncoding. Coding SVs in the top 10% of impact scores had a greater odds ratio
than noncoding variants in the same subset (13.68 for coding, 12.35 for noncoding). The
magnitude of this difference is surprisingly mild and suggests that many non-coding SVs are
under similarly strong selection as coding SVs. To compare the impact of high-scoring deletions
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and tandem duplications, we computed the same odds ratios for variants of these types within the
top 10% of scores. Because duplications tend to be larger than deletions, we sampled SVs from
these sets to make the size distributions approximately equal (see Section 2.5.3). Even when
controlling for size in this way, the odds ratio for tandem duplications with impact scores in the
top 10% was nearly equal to that for duplications (17.68 for deletions, 17.45 for duplications).
This result may suggest that duplications are under stronger selection than previously
thought44,82–84. Alternatively, this result may reflect ascertainment bias against pathogenic
deletions that cause embryonic lethality or severe developmental defects, and thus were not
present in our adult cohort. Further work will be required to disentangle these factors.
To compare SVScore’s ability to distinguish high-impact variants to that of existing
methods, we calculated odds ratios for two naïve alternatives (Alternatives section of Figure
2.3). First, we used SV length percentile alone as a predictor of pathogenicity, categorizing large
SVs (top 10%) as pathogenic and small SVs (bottom 50%) as benign. This yielded an odds ratio
of 14.46, which is slightly greater than the odds ratio of 13.06 when using the top 10% of impact
scores as “pathogenic”; however, substantially fewer rare, pathogenic variants were identified
using the SV length method (1231 vs. 1528). While an SV’s length does influence its
pathogenicity, calculated impact scores from SVScore are more effective predictors of
pathogenicity than length alone. Figure 2.7 shows size distributions for structural variants in our
callset. As impact scores increase, size distributions shift toward larger variants. However, there
is considerable overlap between the distributions, suggesting that while length is associated with
pathogenicity, SVScore captures more information than length alone. Also, the latter method
cannot be easily applied to translocations or other complex variants for which “length” is
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undefined. As a second naïve approach, we defined pathogenicity based on whether or not a
structural variant (in any of its LEFT, RIGHT, or SPAN intervals) overlapped an annotated exon.
This method identified fewer rare, pathogenic SVs (1,070 vs 1,528) and resulted in a lower odds
ratio than using the top 10% of impact scores.
We next sought to calibrate our SV impact scoring method with existing SNP scoring
methods. We first used IMPACT annotations from VEP to define pathogenicity of SNPs in our
callset. SNPs with at least one IMPACT value of HIGH for a canonical transcript were
categorized as pathogenic, while those with only LOW or MODIFIER values on canonical
transcripts were designated benign. This approach was far less effective than SVScore in
discriminating between pathogenic and benign variants. Comparison of SVScore with CADDbased SNP impact scores revealed that the top 10% of highest scoring SVs (N = 1,528) have a
similarly strong allele frequency skew as the top 0.01% of SNPs (N = 1,187). Interestingly, this
result suggests that there may be a similar number of strongly pathogenic SVs and SNPs in the
human population, despite the fact that SNPs are nearly 3 orders of magnitude more abundant
overall.
Finally, we sought to further assess SVScore’s ability to discern common polymorphisms
from pathogenic variation. To this end, we ran SVScore on a manually curated list of
approximately 300 CNVs believed to be pathogenic from ClinGen (iscaCuratedPathogenic in the
UCSC Genome Browser85) as well as the full set of high-confidence SVs detected in phase 3 of
the 1,000 Genomes Project44 . The results, shown in Figure 2.8, demonstrate that the distribution
of ClinGen impact scores is shifted heavily to the right relative to that of 1,000 Genomes and
FinMetSeq SVs.
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A limitation of our method is that it depends on per-base SNP pathogenicity scores, and
thus does not account for all mechanisms whereby SVs may be phenotypically impactful.
SVScore does not optimally address gain-of-function mutations such gene fusions or novel
adjacency with cis-regulatory elements.

2.5.4 Conclusion
SVScore is a novel in silico tool for predicting structural variant pathogenicity. In a large WGS
dataset, its predicted pathogenic variants were more depleted in a Finnish population than those
of alternative methods. SVScore also identified pathogenic SVs in both coding and noncoding
regions. While high-scoring variants tended to be longer, the length distributions of SVs in
different score classes were not sufficiently different to justify using length alone to predict
deleteriousness. Furthermore, we used SVScore to show evidence that tandem duplications are
under similar levels of negative selection as deletions even when controlling for size, although
further work is needed to confirm this.
We believe that SVScore will be a useful tool for future WGS-based studies by enabling
facile prioritization of structural variants based on their likelihood of being deleterious. Its
support for various operations and arbitrary per-base scoring schemes make it a powerful and
flexible asset to investigators interested in the genomic alterations underlying both Mendelian
and complex phenotypes.
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2.6 Aim 1 Conclusion
The first aim of this work is to develop, implement, and evaluate a method for in silico
prediction of structural variant pathogenicity. This was accomplished through the release and
publication of SVScore in Bioinformatics. SVScore is a standalone script that annotates SV VCF
files with pathogenicity scores using a novel per-base score aggregation method. While CADD
was used in the publication in Section 2.5, SVScore could use any per-base pathogenicity scoring
scheme, affording this method great flexibility as genomic annotation methods improve. SVs
with high scores from SVScore had significantly lower allele frequencies than low-scoring SVs,
demonstrating the efficacy of the tool. In applying SVScore to a set of SVs detected in over
1,000 Finnish WGS datasets, a large number of pathogenic noncoding SVs were detected.
Furthermore, SVScore uncovered evidence of unexpectedly strong selection among pathogenic
duplications. SVScore can be a lightweight and useful tool for investigators seeking to study the
impact of SVs on human traits.
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2.7 Figures and Tables

Figure 2.1 Examples of structural variation. Figure credit belongs to Ira Hall (reproduced with
permission).
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Figure 2.2 SVScore strategy. (A) LEFT, RIGHT, and SPAN intervals chosen by SVScore
based on SV type. LEFT and RIGHT scores comprise the entire confidence interval (CI) around
the left and right breakpoint, respectively, and are calculated for every variant type. Here, MEI
refers specifically to mobile element insertions detected in the reference genome, whereas INS
refers to all insertion types detected in the experimentally sequenced genome. For deletions
(DEL), tandem duplications (DUP), and other copy number variants (CNV), a SPAN score is
calculated using the interval between the most likely breakpoints. (B) Truncation scores
(LTRUNC when truncated by the left breakend and RTRUNC otherwise) are calculated for
deletions, inversions (INV), mobile element insertions (MEI), and INS variants that are predicted
to truncate a transcript. BND - “unclassified” structural variant.
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Figure 2.3 SVScore performance comparison. Each point represents the odds ratio of the
definition of “pathogenicity” on the x-axis, and above each point is the number of rare,
pathogenic variants using the same definition. The SVScore Threshold section shows the odds
ratios for pathogenic SVs being rare under varying definitions of pathogenicity based on impact
score percentile, where variants in the bottom 50% were considered benign. The SNP CADD
Threshold section shows odds ratios calculated for SNPs using CADD at the percentile
thresholds shown. For these odds ratios, SNPs with CADD scores in the bottom 50% were used
as benign variants. Pathogenic variants used for calculations in the Top 10% SVScores section
were all subsets of those SVs with impact scores in the top 10%. In this section, the variants in
the bottom 50% of all impact scores were again called benign. For the “Coding” and
“Noncoding” experiments, the pathogenic variants were those SVs in the top 10% of impact
scores that did and did not overlap a refGene exon, respectively. In the “DEL” and “DUP”
experiments, the pathogenic variants were DELs and DUPs, respectively, in the top 10% of
scores. The size distributions of these variants were matched (see Section 2.5.3), and the 95%
confidence intervals are shown. The Alternatives section shows three odds ratios from SVScore
alternatives. In the “Top 10% SV Lgth” experiment, pathogenic variants were those with lengths
at or above the 90th percentile, and benign variants were those below the 50th percentile. For
“Coding SV”, pathogenic variants were those with at least one overlap between refGene exon
and either a breakpoint CI or a SPAN interval, and benign variants were all others. The “SNP
VEP CSQ” experiment used VEP’s IMPACT predictions for SNPs – variants with at least one
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HIGH prediction on a canonical transcript were called pathogenic, while those with only LOW
or MODIFIER predictions on canonical transcripts were categorized as benign.
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Figure 2.4 Variant type composition of SV callset. INV – inversion, MEI – mobile element
insertion, DEL – deletion, INS – novel sequence insertion, DUP – tandem duplication, BND –
unclassified structural variant.
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Figure 2.5 Allele frequency skew of high-scoring structural variants. Variants are separated
first into classes based on impact score percentile, then into allele frequency bins. Each impact
score class is normalized to 1 so that the height of each bar represents the fraction of the given
impact score class that is in the given allele frequency bin. Pathogenic variants are defined as
those with scores in the top 10% of variants in the callset. The odds ratio for this definition of
pathogenicity is 13.06, indicating that pathogenic variants are approximately 13-fold more likely
to be rare (as opposed to common) than benign variants (those in the bottom 50%).
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Figure 2.6 Variant type composition of SVs at or above the 90th percentile of impact scores.
DEL – deletion, MEI – mobile element insertion, DUP – tandem duplication, BND –
unclassified structural variant.
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Figure 2.7 SV distributions separated by SVScore impact scores. SVs in each plot were
placed into logarithmically sized length bins and plotted as histograms. (A) All SVs. (B) Benign
SVs – impact scores below the 50th percentile. (C) Intermediate SVs – impact scores below the
90th percentile and at or above the 50th percentile. (D) Pathogenic SVs – impact scores at or
above the 90th percentile.
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Figure 2.8 Variant score distributions. (A) Distribution of precomputed CADD SNP scores on
chromosome 1. The inset shows a zoomed view of the score distribution between 25 and 60. (B)
SVScore impact score distribution for SVs in phase 3 of the 1,000 Genomes Project (blue) and
known pathogenic SVs from ClinGen (red). These variants are sampled such that they come
from the same size distribution (see Section 2.5.3). Irregularities around 30 in the impact score
distribution are likely a result of the irregularity in the CADD distribution at the same score
(shown in the inset of panel (A)). (C) Same as (B), but comparison is made with FinMetSeq, the
same 1,355 Finnish genome data set used for analysis in the main text of the paper. The red
distributions differ from one another in that panel (B) is sampled so the size distribution matches
that of the 1,000 Genomes Phase 3 SVs, while that in panel (C) is sampled to match the size
distribution of the FinMetSeq data set. All variants above 1 Mb in length were excluded, as
SVScore automatically assigns these variants a score of 100.
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Table 2.1 SVScore performance statistics, in seconds. LEFT/RIGHT, SPAN, and
LTRUNC/RTRUNC lines reflect the average number of seconds elapsed per variant while
computing a score, while the Preprocessing and Postprocessing lines reflect the time elapsed
while performing one-time computations. Score Extraction refers to using tabix to extract perbase scores from the score file, while Score Processing refers to the average time spent
aggregating scores using each of the following operations: maximum, sum, mean, mean of the
top 10 bases, and mean of the top 100 bases (all three mean operations were weighted by
probability distributions around each breakend).
Total

Score Extraction

Score Processing

Preprocessing

156.7

-

-

LEFT/RIGHT

0.199

0.160

0.026

SPAN

0.485

0.134

0.320

LTRUNC/
RTRUNC

2.1 per transcript
4.597 per variant

0.201

1.762

Postprocessing

139.7

-

-
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Table 2.2 Contingency table for FinMetSeq SVs at varying impact score thresholds.
SV Percentile

Rare

Common

Bottom 50%
Top 1%
Top 5%
Top 10%
Top 15%
Top 20%
Top 25%
Top 30%
Top 35%
Top 40%
Top 45%

2846
180
772
1528
2212
2845
3449
3983
4536
5032
5561

5420
12
119
222
351
547
754
1032
1294
1623
1934

42

Chapter 3: Aim 2 - Genetics of Mitochondrial
DNA Copy Number and Its Relationship to
Metabolic Syndrome
3.1 Introduction
Mitochondrial DNA copy number (MT-CN) is a measurement of mitochondrial content of a
tissue obtained by quantifying the amount of mitochondrial DNA (mtDNA) present. We became
interested in this phenotype in the course of a multi-trait GWAS of SVs performed by Lei Chen,
another member of the Hall research group86. This interest arose from a test for associations
between copy number windows (CNWs) and cardiometabolic traits using the same set of Finnish
WGS samples described in Section 1.4. In the course of that work, Lei observed several CNWs
at two loci exhibiting strong associations (strongest P < 10-12; Figure 3.1 and Figure 3.2) with
fat mass and fasting serum insulin. These CNWs had abnormal copy number range, strong
genotype correlation, and overlapped annotated nuclear mitochondrial insertion sites (NumtS) regions of the nuclear genome with high homology to the mitochondrial chromosome (likely the
result of ancient insertions of mitochondrial DNA into the nuclear genome87). She then measured
MT-CN directly using sequencing coverage of the mitochondrial genome (see Section 3.7.3) and
found that the strength of these trait associations increased (Figure 3.2), suggesting that the
NumtS associations were simply a result of reads from the mitochondrial chromosome
erroneously aligning to NumtS regions. In other words, the NumtS signals were actually proxies
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for two underlying associations between MT-CN and both fat mass and insulin. In fact, Lei
found that MT-CN has strong associations with many tested metS traits (Figure 3.3A).
I then undertook an in-depth study of this strong, inverse relationship between MT-CN
and metS phenotypes, presented here. The aims of this work are restated below, as first set forth
in Section 1.5:
❏ Aim 2: Interrogate the genetics of peripheral blood mitochondrial DNA copy
number (MT-CN) and its relationship to metabolic syndrome
❏ Aim 2a: Investigate the germline genetic determinants of peripheral blood
MT-CN in Finns
❏ Aim 2b: Assess the evidence for a causal relationship between MT-CN and
fasting serum insulin in Finns
❏ Aim 2c: Utilize UK Biobank data to replicate and interpret the association
between MT-CN and metabolic syndrome
The work in Aim 2 is detailed in the manuscript reproduced in Section 3.7. In contrast to Aim 1,
in which SVScore - which addressed a problem not well treated in the literature - was
introduced, there is substantial prior work that bears discussing in this Chapter. As a result, the
state of the field is described in detail in Sections 3.2-3.5.
While mitochondrial content has been studied extensively, many studies in the literature
are limited by small sample sizes and low statistical power. Further complicating the
interpretation of this work is the heterogeneity of mitochondrial quantitation methods. Real time
polymerase chain reaction (rtPCR)88, quantitative polymerase chain reaction (qPCR)89, WGS90,
and microarray91 data have all been used to measure MT-CN, while cardiolipin measurement92
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and assays for citrate synthase93 and cytochrome C oxidase94 activity have been employed as
orthogonal methods to quantify mitochondrial content. Although a recent study found WGS to be
the most reliable measurement of MT-CN95, few studies have utilized this method90,96. The result
is a body of literature with varying levels of reliability. Nevertheless, it is worth discussing the
work that has been done on this subject to place the present study in context. Although there is
extensive prior work to be discussed, the lack of consensus and clarity leave a need for the study
presented in Section 3.7.

3.2 Genetics of Peripheral Blood MT-CN
While MT-CN has been studied in detail in many tissues (see Section 3.3), the manuscript
reproduced in Section 3.7 deals with the genetics of MT-CN in peripheral blood. Thus, this
Section will focus mainly on peripheral blood MT-CN.
The heritability of peripheral blood MT-CN has been established in several studies. A
multi-ethnic study of 375 twins and their siblings estimated 65% heritability (95% CI: 50%72%) of MT-CN measured by quantitative rtPCR97. Curran et al.98 used rtPCR to quantify MTCN in 1,259 Mexican-American individuals from 42 families, estimating heritability at 33%.
They also estimated 52% heritability in a cohort of 1,088 individuals of European descent98.
Only one study has addressed the question of peripheral blood MT-CN heritability using
sequencing. This study, performed by Ding et al.96, calculated 54% heritability in a cohort of
2,077 Sardinian individuals. Cai et al.90 used low-coverage (1.7x) sequencing data from 10,442
Chinese women to estimate 15.6% heritability (5.1% SE); however, these samples came from
buccal swabs rather than blood. While absolute heritability values are not always comparable,
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especially across different study designs, the above work does establish that MT-CN is a highly
heritable trait.
A small number of quantitative trait loci (QTLs) associated with MT-CN have been
identified. Using linkage analysis in their study of Mexican-Americans, Curran et al.98 reported a
significant linkage peak on chromosome 10q11 at 72 cM, a suggestive peak on chromosome 8 at
41 cM, and evidence for significant linkage on the mitochondrial chromosome. Both the
chromosome 10 QTL and the mitochondrial chromosome linkage were replicated in the
European cohort. Furthermore, using their saliva samples in Chinese women, Cai et al.90
reported 2 significant lead markers, both of which replicated in an independent cohort of bloodderived samples: rs11006126 and rs445. Notably, rs11006126 is located on chromosome 10q21,
the chromosomal band adjacent to that on which Curran et al. identified a linkage peak. Finally,
in a recent GWAS meta-analysis of 6,799 Europeans using array data and qPCR-measured MTCN, Guyatt et al.99 found two suggestive, but not genome-wide significant, signals at lead
markers rs12873707 and rs709591.

3.3 Relationship Between Mitochondria, Metabolic
Syndrome, and Cardiovascular Disease
As discussed in Section 1.1, metS refers to an array of disorders which increase the risk of CVD
and type 2 diabetes mellitus (T2D); some examples of these disorders include obesity, insulin
resistance, dyslipidemia, and hypertension. Many associations are described in the scientific
literature between these traits and mitochondria, although most of these studies are limited as
described in Section 3.1. As a result, some reports claim associations with directions of effect
that disagree with the inverse relationship between MT-CN and metS observed in the present
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work (Section 3.7) and the rest of the literature. These cases will be highlighted using asterisks
(*) in order to emphasize the disagreement in the literature about the directions of these
effects.
Prior work has described associations between CVD and mitochondrial traits including
mitochondrial dysfunction and biogenesis as well as MT-CN100. Some small studies (N = 756
and 400) have reported an association between peripheral blood MT-CN and either risk or
severity of CHD101,102. Impaired mitochondrial biogenesis and function have been identified as
risk factors for metabolic cardiomyopathy100 and T2D103. Decreased MT-CN has also been
shown to be associated with increased CVD risk in two recent, large studies. In one, Ashar et al.
show this association in 21,870 individuals by measuring MT-CN by qPCR in one cohort and
microarray probe intensities in two others104. This study was included in a large meta-analysis of
similar studies totaling 29,156 samples that used qPCR and microarray data to quantify MT-CN,
resulting in the same conclusion105.
Similar results have been shown with metS, although this is not surprising given the
known association between metS and CVD. Mitochondrial function and biogenesis have been
associated with insulin resistance and secretion100,103, obesity100,106, and metS more
generally100,106. One meta-analysis of two cohorts (total N = 5,150) performed by Guyatt et al.
found evidence of an association between qPCR-measured MT-CN and serum insulin levels in
one cohort, although this signal did not survive meta-analysis107. However, a study of buccal
samples from 75 obese children108 found positive correlations between rtPCR-measured MT-CN
and both BMI and waist circumference*. The latter two studies tested several other metS traits,
finding no significant associations.
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3.3.1 Caveats
Two caveats to this literature review are important to consider. First, these mitochondrial
associations may be tissue-specific. In one review, Szendroedi et al. mention that there is
evidence for association between altered mitochondrial function or abundance in insulinresponsive tissues109. They discuss this evidence for skeletal muscle, liver, heart, adipose, and
brain tissue. Kim et al. make this same observation about multiple tissues in the presence of
insulin resistance, particularly skeletal muscle, liver, and adipose tissue103. They do not mention
peripheral blood, although there is evidence for mitochondrial associations there as well; some of
this evidence has been listed in this Section, and more will be discussed in Section 3.3.3.
The other caveat is that given that different cell types can have different mitochondrial
content, overall MT-CN can be explained by a combination of blood cell mitochondrial
abundance and cell type composition. This has largely been ignored in prior work, and will be
discussed in detail in Section 3.7. In one notable exception, Cai et al. used CpG methylation
(which varies by cell type) as a proxy for cell type and found that cell type composition was not
significantly different at the extremes of the MT-CN distribution110. However, this study was
done using saliva samples, and no similar experiment was performed in blood.

3.3.2 Mitochondrial Associations with Cardiometabolic Disease Outside of
Blood
Associations between mitochondrial traits and both metS and T2D have been reported in adipose
tissue in both humans and mice. For example, reduced mitochondrial content and function have
been shown in white adipose tissue of T2D patients111. Moreover, adipocytes in morbidly obese
individuals or those with T2D had both decreased mitochondrial content and decreased
expression of genes associated with mitochondrial biogenesis 103. Finally, a study of the 100
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transcripts in murine adipose tissue that were most strongly correlated with body mass found that
12 of these transcripts coded for mitochondrial proteins112. All of these correlations were
negative, recapitulating the direction of the effect described in Section 3.7.
Mitochondrial traits are also associated with metS and related disorders in liver tissue.
Lower hepatic mitochondrial content in offspring has been shown to be associated with a high fat
diet in mother mice113. In addition, liver mitochondrial content was found to both be associated
with insulin resistance and be lower in non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatosis114,115. Small studies suggest that despite a paradoxical increase in
mitochondrial content*, impaired liver mitochondrial biogenesis and capacity are present in
obesity-associated nonalcoholic steatohepatitis111. Finally, a very small (N = 7) study of a mouse
model of obesity found increased plasma insulin levels and reduced mitochondrial protein
content in the liver116.
Similar associations have been observed in skeletal muscle tissue. One review by Ren et
al. claims that increased mitochondrial biogenesis contributes to insulin resistance in skeletal
muscle*, although the authors also claim that mitochondria in skeletal (and heart) muscle are
reduced in both number and size in insulin resistance and obesity100. In diabetes and obesity,
muscle has lower mitochondrial activity and MT-CN, and mitochondria are smaller and
abnormal in structure93,109,117. Decreased numbers of skeletal muscle mitochondria have been
reported in insulin resistant individuals103 as well as T2D patients118. In fact, skeletal muscle
mitochondria have been found to be reduced in number by 30% in T2D, insulin-resistant obese
individuals, and even first-degree relatives of individuals with T2D, and obese T2D patients can
have up to 40% fewer muscle mitochondria111. Moreover, a study in mice found that expression
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of the gene ROCK1, whose product is a serine/threonine protein kinase, both decreases MT-CN
and impairs insulin sensitivity in muscle, suggesting a shared regulatory pathway119. Finally, a
small study (N = 25) of adult humans found that mitochondrial content in skeletal muscle was
negatively associated with BMI and adiposity, but positively correlated* with fasting serum
insulin and insulin resistance.
Associations between mitochondrial traits CVD have been observed in other tissues as
well. For example, a study of model organisms and human specimens found that accumulated
(i.e. not heritable) mtDNA damage was associated with atherosclerotic lesions in aortic tissue
from humans and model organisms120. Importantly, this work also showed that mtDNA damage
precedes these lesions, suggesting that the former may be causal for the latter. In addition, a
study of a mouse model of myocardial infarction found mtDNA damage, decreased MT-CN, and
decreased mitochondrial function associated with heart failure121.

3.3.3 Mitochondrial Associations with Cardiometabolic Disease in Blood
Peripheral blood, the tissue most relevant to the present work, has also been shown to display
similar associations between mitochondrial and cardiometabolic traits. Several studies linking
MT-CN to metS and CVD101,102 have already been described in Section 3.3, including the wellpowered studies by Guyatt et al.107 and Ashar et al.104 Although Guyatt et al. detected an
association with insulin levels in one of their two cohorts, eleven other cardiometabolic traits
were tested and no significant associations were detected. Another well-powered effort to
address this question is the Ding et al.96 study mentioned in Section 3.2. This work found lower
WGS-measured blood MT-CN to be significantly associated with higher waist-hip ratio and
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waist circumference in approximately 2,000 Sardinians; interestingly, these MT-CN associations
did not extend to BMI or lipid traits.
Several small studies have also addressed this question with varied results. One such
analylsis of 144 postmenopausal women found that rtPCR-measured blood MT-CN was
negatively associated with several metS traits including fasting insulin, waist circumference,
total cholesterol, and triglyceride levels122. Another small study (N = 134) found associations
between lower MT-CN and both decreased insulin sensitivity and decreased* chance of
developing glucose intolerance or diabetes123. This work disagreed with a slightly larger study (N
= 282) as to whether lower MT-CN correlated with status as offspring of a T2D patient, with the
latter claiming lower MT-CN was associated with not* being an offspring of a diabetic
individual124. Finally, an analysis of rtPCR-measured MT-CN in 295 individuals found that
lower MT-CN was associated with having neither T2D nor impaired fasting glucose*; however,
this signal was no longer significant after correcting for fasting glucose125.

3.3.4 Genetic Variants in Mitochondrial Genes Associated with
Cardiometabolic Disease
Many variants on the mitochondrial chromosome have been shown to be associated with
cardiomyopathy, suggesting a mitochondrial etiology. Marin-Garcia et al. list 21 such variants
and the specific disorders with which they associate126. One of these variants, an A→G
substitution at position 3243 associated with dilated cardiomyopathy, is also associated with
impaired insulin secretion103. This is not surprising, as mutations of the mitochondrial
chromosome can cause diabetes by damaging the ability of pancreatic cells to secrete insulin103.
Mutations in the promoter of UCP2, a nuclear-encoded mitochondrial protein, are associated
with lowered insulin secretion in addition to positive T2D status103.
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Particular mitochondrial haplogroups also have known associations with cardiometabolic
disease. Haplogroup N9a is reportedly protective against metS in Japanese women 127 and against
T2D in individuals of Asian descent128. Haplogroup N9b has also been shown to protect against
myocardial infarction in Japanese men129. However, another study found no association between
mitochondrial haplogroups and NAFLD130.

3.3.5 Causality
Some evidence points toward a causal role for mitochondrial content and/or function in the
etiology of metS106. For example, the inherited genetic alterations in mtDNA discussed in
Section 3.3.4 imply a causal role for mitochondrial dysfunction in metS. This is supported by the
fact that patients with mitochondrial diseases often develop vascular complications at an early
age, even without typical risk factors for atherosclerosis 131.
Beyond mitochondrial dysfunction, there is also evidence for a causal role for decreased
mitochondrial content and biogenesis in cardiometabolic disease. For example, therapeutics
targeting deficiencies of mitochondrial biogenesis can ameliorate metabolic dysfunction 100.
Stimulation of mitochondrial biogenesis can also resensitize liver, adipocytes, and heart tissue to
insulin103. Reduced mitochondrial biogenesis has also been implicated in metabolic
cardiomyopathy in many studies100. Szendroedi et al. propose decreased mitochondrial
abundance as an explanation for the impaired resting mitochondrial activity levels observed in
hereditary insulin resistance.
Despite this wealth of evidence pointing toward a strictly causal relationship between
mitochondria and cardiometabolic disease, some studies disagree. For example, one review
claims that the relationship between insulin sensitivity and mitochondria is bidirectional and
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dependent on both the tissue of interest and the particular mitochondrial trait being discussed 111.
Moreover, there is some evidence of a positive feedback cycle between mtDNA damage and
reactive oxygen species (ROS) that leads to atherosclerosis and insulin resistance103,120,131.
Another review claims that muscle mitochondrial content increases before insulin resistance
begins but decreases as it gets more severe132. The authors interpret this to mean that decreases in
muscle mitochondrial content are a result, not a cause, of insulin resistance. They also cite an
observation that obese, insulin-resistant individuals have impaired insulin-stimulated translation
of mitochondrial proteins.

3.3.6 Possible Mechanisms
ROS-based Mechanisms
A wealth of evidence suggests that ROS play a crucial role in the association between
mitochondria and cardiometabolic disease. As mentioned in Section 3.3.5, several sources
emphasize the positive feedback loop between ROS and decreased mitochondrial function and
abundance, as well as this loop’s relationship to metS and CVD 103,120,131.
Increased oxidative stress may be a result of activation of the renin-angiotensinaldosterone system and may result in apoptosis or degradation of mitochondria100. It has been
proposed that mitochondria are especially sensitive to ROS for two main reasons 117. First, these
organelles lack nucleotide excision repair mechanisms, so heavy DNA damage must be handled
by DNA degradation. In addition, the mitochondrial genome lacks histones and is located near
the inner mitochondrial membrane, the main cellular source of ROS, both of which predispose
mtDNA to oxidative damage. This is supported by the observation that in mice, ROS produced
in vascular tissue may damage mtDNA and be a precursor to atherosclerosis120.
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In contrast, two small studies (N = 296 and 156) found that peripheral blood leukocyte
MT-CN actually increases* in response to oxidative stress125,133, one of which claimed this
increase in MT-CN is related to hyperglycemia rather than insulin resistance125.
Some research has suggested that ROS leads to cardiac failure via apoptosis 126. Also,
mice with a genetic deletion of a base excision repair enzyme have been observed to have
increased mtDNA damage and deletions and develop obesity with dyslipidemia, fatty liver
disease, and hyperinsulinemia106,134. This link between DNA damage and metS supports a role
for ROS in the pathogenesis of cardiometabolic disease.
ROS-independent Mechanisms
Several ROS-independent mechanisms may explain the association between mitochondria and
cardiometabolic disease. For example, mitochondrial activity may respond to calcium ion
concentrations (via either the citric acid cycle or ATP synthase activity), which can lead to
cardiac failure126. Alternatively, thyroid hormone is known to stimulate both mitochondrial
biogenesis and weight loss, potentially explaining an inverse association between MT-CN and
metS135. Another explanation is the stimulation of mitochondrial biogenesis by aerobic exercise which stimulates expression of regulatory genes such as PGC-1, NRF-1, and TFAM - as well as
calorie restriction103. Finally, resistin has been shown to lower hepatic MT-CN both in vitro and
in mouse models via a PKC/PKG/p65/PGC-1α signaling pathway, leading to hepatic steatosis136.
In mice, resistin also increased serum triglyceride, glucose, and insulin levels as well as insulin
resistance; the change in MT-CN occurred before increases in fat and insulin resistance136.

3.4 Relationship Between Inflammation and metS
A crucial observation in the manuscript reproduced in Section 3.7 is that peripheral blood
MT-CN may be a proxy for inflammatory status in its relationship to metS due to varying cell
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type composition of the blood. As a result, it is worth mentioning briefly that the relationship
between inflammation and metS has been addressed in the literature. In their review, Saltiel and
Olefsky discuss the links from inflammation to obesity and, in turn, obesity to metabolic disease,
particularly insulin resistance and defective insulin secretion137. They also mention that the
association between insulin resistance and inflammation is direct, and that the evidence
supporting it is overwhelming. They claim that inflammation is initially adaptive in order to
relieve the “anabolic pressure” resulting from obesity, but can become harmful if left unresolved.
Importantly, however, this review focuses mostly on muscle, liver, and adipose tissue and does
not address inflammatory markers in blood.
Some other studies have found blood cell count indices to be associated with CVD. For
example, a recent review mentions known associations between neutrophil-to-lymphocyte ratio
(NLR) and both inflammatory status and CVD mortality138. The directions of these effects are
consistent with those found in Section 3.7. The same review discusses evidence of associations
between platelet-to-lymphocyte ratio (PLR) and all-cause mortality, acute coronary syndrome,
and various other forms of CVD. While the directions of effect are consistent with those found in
the study in Section 3.7, the cited studies were very small (N < 200), and the authors mention
that further study is necessary given that published literature is not all in agreement on the
existence of these effects. Several other studies have proposed PLR as a prognostic marker for
CVD139–141, with directions of effect largely, though not entirely, agreeing with those expected
from the present study.
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3.5 Mendelian Randomization
Mendelian randomization (MR) is a statistical method that utilizes genetics to infer causality
from observational data. MR is central to Aim 2B, and a modified version of the method was
developed to take maximum advantage of the available Finnish data while addressing the
question of causality. A review of the MR literature is provided in this Section in order to explain
the statistical basis of MR, justify the decisions made in modifying it, and place the modified
version in the context of other MR-based methods.

3.5.1 Overview
Mendelian randomization was originally proposed by Katan in 1986 as a way to leverage the
association between ApoE genotypes and cholesterol to test for a causal effect of cholesterol in
cancer142. Katan’s proposal was an epidemiological application of instrumental variable (IV)
methods developed in econometrics143,144. This iteration was conceived exclusively as a test of
causality between two variables (in Katan’s case cholesterol and cancer), although later work
enabled the estimation of the magnitude of the effect between these variables (see below).
Typically, MR is formulated as a test for causality between an exposure (X) and an
outcome (Y) using a genetic instrument (Z), typically a single genotype, known to be associated
with X (Figure 3.4). Furthermore, some confounders (U) for the exposure-outcome association
may be present, and they may be measured or unmeasured. In the example from Katan,
cholesterol is the exposure, cancer is the outcome, and the genetic instrument is the ApoE
genotype. In this formulation, the test for causality of X on Y is a test for association between Y
and Z assuming that Z is a suitable proxy for X. Under this assumption, formalized in Section
3.5.2, a change in Z would only lead to a change in Y if X causes Y. Intuitively, this can be
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compared to a randomized control trial for the effect of X on Y in which genetic subgroups
(defined by the genetic instrument, Z) are analogous to the treatment and control arms, as Z is
associated with X145. As discussed in below, such a trial can still be said to be randomized
because of Mendel’s laws, which gives the method its name146. The appeal of this method comes
from its ability to infer causality from observational data, an nontrivial feat.
Modern MR can use this framework to estimate the size of the causal effect of X on Y.
Using the Wald method, this is done as follows: 𝛽̂𝐼𝑉 = 𝛽̂𝑍𝑌 /𝛽̂𝑍𝑋 , where 𝛽̂𝐼𝑉 is the instrumental
variable (IV) estimate of the effect of X on Y, 𝛽̂𝑍𝑌 is the observed regression coefficient of Y on
Z, and 𝛽̂𝑍𝑋 is the observed regression coefficient of X on Z144,147.
The main advantage of MR is that under the assumptions listed in Section 3.5.2, the
exposure-outcome effect estimate remains unbiased in the presence of endogeneity such as
regression dilution bias, e.g. measurement error and confounding in the relationship between
exposure and outcome144. Endogeneity can be assessed post hoc using the Durbin-Wu-Hausman
statistic to compare the ordinary least squares effect estimate of the exposure-outcome effect
with the IV estimate; if the null hypothesis is rejected, this suggests that the IV analysis is
necessary.144
MR even remains unbiased in the presence of unmeasured confounders, provided that the
assumptions hold144,148. Fundamental to this method is the observation that due to Mendel’s law
of independent assortment, genetic variants are much less frequently associated with confounders
than are the exposures for which they serve as proxies146,148. For example, even if the
cholesterol-cancer association studied by Katan were confounded by diet, ApoE genotype is
unlikely to be associated with diet as well, so the assumptions are likely to hold. Genetic variants
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are also less likely to be subject to reverse causation, a violation of the assumptions described in
Section 3.5.2, as exposure levels rarely affect genotypes148. Another advantage of testing
exposure-associated genotypes instead of the exposure levels themselves is that genotypes are
likely to indicate long-term exposure levels, whereas individual measurements can only assess
exposure levels at a given point in time146. Furthermore, as genotyping tends to be very accurate,
MR reduces the effect of measurement error inherent in using measured exposure values 148.
Finally, the genetic instrument chosen does not even have to be causally related to the exposure
in order for the MR assumptions to hold; so long as Z and X are associated, this method can be
used to infer causality144.
Some researchers have employed a bidirectional strategy with MR149. In this approach,
after calculating the IV effect estimate, the exposure and outcome are switched and the IV
estimate is recomputed. Ideally, one estimate will be zero and the other will be nonzero, making
the true direction of causality clear. However, this strategy requires having valid genetic
instruments for both the exposure and the outcome. Furthermore, this assumes that causality
occurs in a single direction, which is violated by feedback loops148.

3.5.2 Assumptions
Three assumptions are necessary for MR to claim an unbiased causality test of the exposureoutcome association148,150–152. These are:
1. Relevance: Z is associated with X
2. Exclusion restriction: Z is independent of Y except through X and U
3. Independence: Z is independent of U
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Furthermore, to achieve an unbiased estimate of the exposure-outcome effect, an extra
assumption is necessary that all associations are linear and that statistical interactions are
absent144,145.
Testing Assumptions
Assumption 1, the relevance assumption, is the only one that can be tested directly 148.
Nevertheless, assumptions 2 and 3 can be assessed by testing for associations between Z and
possible confounders. These assumptions can be deemed plausible if no more associations are
found than expected by chance, although, ideally, no associations would be found 148. Another
way to test for assumption violations is to use several instruments in parallel and compare the
resulting 𝛽̂𝐼𝑉 values144. Similar results would suggest that assumptions 2 and 3 are not
violated144.
It is often tempting for researchers to regress the outcome on the instrument both with
and without adjustment for the exposure to test the exclusion restriction. Researchers who use
this method often expect the instrument-outcome association to disappear when adjusting for the
exposure if the exclusion restriction is valid, as this assumption claims that there are no paths
from Z to Y in Figure 3.4 that do not go through X. However, this approach is misguided; not
only can adjusting for X induce collider bias, resulting in a biased effect estimate, but this also
ignores the fact that measurement error in the exposure means that the instrument-exposure
association shouldn’t disappear upon adjustment for the exposure148.
Assumption Violations
The main disadvantage of MR is that its assumptions are somewhat strong and their
violation can result in biased results. The need for the association between genotype and
exposure (the relevance assumption) to be reliable is often repeated in the literature144,146,150.
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Ebrahim and Davey Smith take this requirement further, advising that genetic instruments should
be common variants with well-characterized function146. Also, weak instruments (genetic
variants explaining a small percentage of the variance of the exposure) yield biased effect
estimates and artificially small confidence intervals 144. This can be thought of as an overfitting
issue in which the instruments explain random variability in the confounders 145. Stronger
instruments are more robust to this147. Furthermore, finite sample bias is common to all IV
estimates; this usually biases the effect estimate in the direction of the confounding147.
The exclusion restriction is a particularly strong assumption and can be violated in
numerous, sometimes subtle, ways. For example, horizontal pleiotropy leading to a direct
association between Z and either U or Y violates the exclusion restriction145,151. Perhaps less
obvious, however, is the fact that linkage disequilibrium (LD) between Z and another outcomeassociated variant also violates the exclusion restriction144,146,150,151. Moreover, even weak
population stratification violates the exclusion restriction and can confound MR144–146,150,
because if the outcome differs across this structure, spurious genotype-exposure associations
with ancestrally informative polymorphisms can be induced151. Another exclusion restriction
subtlety is that ascertainment of samples based on disease status can violate this assumption if
the disease is associated with the exposure and the outcome150. This occurs because Z is still
associated with Y even after adjusting for X due to of the connection through the disease status150.
Finally, reverse causation, such as feedback loops, can violate the exclusion restriction, leading
to a biased IV effect estimate150.
Because each of these assumption violations lead to a bias, negative MR results are more
believable than positive results as long as sample sizes are large150. The reason for this is that if
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an IV estimate is 0, any biases would have to align perfectly for this to be a false negative;
conversely, a nonzero effect estimate could easily be the result of bias if the true causal effect is
null150.

3.5.3 Multiple Variant MR
TSLS, LIML, and GMM
The descriptions of MR above assume that Z represents the genotype at single genetic locus.
However, several strategies have been developed to allow for MR analyses using multiple
variants, including Two Stage Least Squares (TSLS) regression, Limited Information Maximum
Likelihood (LIML), and Generalized Method of Moments (GMM)144.
TSLS (or 2SLS) regression is so named because the final estimate is the same as doing
the regression is two stages (although the standard error of the estimate is different) 144. In stage
1, the exposure is regressed on the instrument, and stage 2 then regresses the outcome on the
stage 1 predicted exposure values144. In the first stage, parsimonious models are advantageous in
order to avoid including weak instruments144. As the fit of the first stage regression is important
to avoid weak instrument bias, the F statistic of this regression is typically calculated to
determine whether the results are likely unbiased. An F statistic threshold of 10 has been used for
this purpose144, although some investigators argue against such a hard threshold because weak
instrument bias is a continuous, not binary, phenomenon and because the expected - not observed
- F statistic determines bias145,147.
In TSLS, the R2 of the first stage regression is crucial in determining statistical power,
not the number or frequencies of IVs153. Thus, it has been suggested that IVs be combined into
allele scores (see below) in GWAS applications in order to overcome the weak IV problem
without losing too much power153. To increase precision, it is also possible to adjust for
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covariates in TSLS, although this can lead to bias if these covariates are in a causal pathway, are
colliders, or are downstream of colliders147.
LIML is the maximum likelihood equivalent of TSLS; this method uses maximum
likelihood to estimate the causal effect147. Despite this approach being robust to weak
instruments, it is somewhat controversial as its estimates have undefined moments 147.
Meanwhile, GMM is a semi-parametric, flexible form of TSLS designed to deal with nonlinearities in the two-stage equations and heteroskedastic error distributions147.
Allele Scores
Another method to utilize multiple genetic variants in an MR analysis is to combine the
genotypes into an allele score149,154. The allele score is then used as a single instrument. This
approach can increase statistical power because allele scores can explain more of the exposure
variance than a single instrument148. Allele scores are unbiased, even with misspecification of the
allele score, e.g. nonlinearity, unequal effect sizes, and interactions 145. However, IV assumption
violations can still result in biased effect estimates, so each individual variant must be a valid
IV145. In fact, allele scores can be biased even if only 10% of the included variants are invalid 145.
Allele scores can be weighted or unweighted. In general, simulations have shown that
weighted scores have better statistical power than unweighted scores, especially when effect
sizes vary among the included variants145. When effect sizes are somewhat uniform, allele scores
can yield more precise effect estimates, even when scores are unweighted or if the weights are
misspecified147. An important consideration for allele score-based MR is that the same data
should not be used to estimate the exposure-outcome effect and derive weights (or choose
variants), unless using cross-validation145. Otherwise, simulations show that the resulting effect
estimates can be biased due to winner’s curse145,148.
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One-sample and Two-sample MR
Newer MR techniques are divided into two categories: one-sample and two-sample. One-sample
methods utilize a single cohort with genotype, exposure, and outcome data, while two-sample
methods measure instrument-exposure and instrument-outcome effect sizes in separate data sets.
In two-sample MR using multiple variants, the exposure-outcome effect is often estimated as the
regression coefficient from the weighted linear regression of the instrument-outcome effect sizes
onto the instrument-exposure effect sizes (weighted by the inverse variance of the instrumentoutcome effects)155,156 with the intercept constrained to zero. Another interpretation of this is as
the slope of the best fit line on a scatterplot comparing the instrument-exposure effect sizes with
the instrument-outcome effect sizes, as long as the line crosses the origin. This is known as the
inverse-variance weighted (IVW) method.
One advantage of two-sample MR methods is their ability to use summary statistics, thus
allowing for larger sample sizes and, consequently, higher statistical power 148,157. However, the
two datasets used must be non-overlapping while describing the same population and have
similar age and sex distributions in order to avoid biased exposure-outcome effect estimates148.
Meanwhile, one-sample MR is better for examining violation of the IV assumptions and adding
precision to the effect estimates144. Furthermore, one-sample MR allows for exclusion of the
possibility that genotyping errors are responsible for null instrument-outcome associations144.
Interestingly, weak instrument bias acts in opposite directions in these two frameworks, biasing
the resulting effect estimate away from the null in one-sample MR and toward the null in twosample MR148.
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Pleiotropy Adjustment Strategies in Two-sample MR
As discussed in Section 3.5.2, horizontal pleiotropy can bias MR results if it leads to a violation
of the IV assumptions. To address this issue, several extensions to two-sample MR have been
developed that adjust for horizontal pleiotropy. For example, MR-Egger regression is a type of
two-sample MR that relaxes the exclusion restriction assumption by allowing an intercept term
in the IVW regression described above148,158. In this case, the intercept provides an estimate of
the degree of pleiotropy and the slope represents the pleiotropy-adjusted exposure-outcome
effect estimate148,158. Despite the relaxed exclusion restriction assumption, MR-Egger regression
assumes that the magnitude of each instrument-exposure effect size is independent of its
pleiotropic effect size157. Additionally, the simulation extrapolation (often referred to as SIMEX)
method corrects MR-Egger regression for the effects of measurement error157.
Weighted median and weighted modal regression are two MR techniques that relax the
IV assumptions using multiple genetic instruments157,159,160. Weighted median regression
involves taking a median of the individual-variant ratio estimates (as defined in Section 3.5.1),
weighted by the inverse variance of each estimate159. This method consistently estimates the true
exposure-outcome effect as long as at least 50% of the weight comes from valid IVs159.
Meanwhile, weighted modal regression uses the mode of an empirical density function of all
ratio estimates; this method operates under a different set of relaxed assumptions than does
weighted median regression160.
Another two-sample MR method is known as General Summary MR (GSMR)161. Like
many of the above methods, GSMR uses only summary statistics, so it does not require access to
individual-level data. GSMR has higher power than the IVW method because it considers the
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sampling variation of the effect estimates of the instrument on the exposure and the outcome.
However, this method requires ten or more independent genome-wide significant instruments.161
In practice, multiple MR methods can be used as sensitivity analyses in the same study.
As an example, Gage et al. use 3 methods with different underlying assumptions to estimate a
causal effect between education and smoking157. These methods are: 1) MR-Egger and SIMEX,
2) weighted median and weighted modal regression, and 3) searching for dominating instruments
using Cook’s distance and Studentized residuals.
Other MR Extensions
Several other extensions to MR have been proposed to avoid bias from invalid instruments. Kang
et al. propose a method of finding invalid instruments using LASSO regression162. Although
Windmeijer et al. find that this approach does not consistently identify invalid instruments when
those instruments are strong, they show that a median-type estimator is consistent if less than
half of the instruments are invalid163. That is, the median of L IV estimates for L possible
instruments is a consistent estimator for the true causal effect as long as at least L/2 instruments
are valid163. Windmeijer et al. also propose an adaptive LASSO method for finding valid
instruments and estimating causal effects163.
Furthermore, Cho et al. propose adjusting for pleiotropy by using TSLS with an
interaction of genotype and sex as the IV and fitting a second stage model with an explicit term
for the pleiotropic effects of the instrument on the outcome164. Spiller et al. propose MRGxE to
extend this approach to work with summary statistics and relax the linearity assumption from the
explicit modeling of pleiotropy in the stage 2 linear regression165. However, this method depends
on having subgroups of data for which instrument-exposure and instrument-outcome associations
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are expected to vary due to an interaction with another covariate (e.g. sex in the example from
Cho et al.)165.

3.5.4 MR Strategy in the Present Study
In the manuscript reproduced in Section 3.7, a novel MR strategy is presented that was
developed with the above considerations in mind. Among the principal considerations in creating
this approach was the fact that the genetics of MT-CN (the exposure) are not well characterized.
As a result, there were few reliable variants to choose as a genetic instrument. For this reason as
well as the limited sample size, we chose an allele score approach, combining multiple variants
into a polygenic score and increasing statistical power. Because of the paucity of known MT-CN
associated variants, this score was constructed using our own data in a way analogous to crossvalidation to avoid the winner’s curse problem described in Section 3.5.3.
Another consideration was the availability of rich phenotypic data in the Finnish data
being analyzed. This allowed for the possibility of adjustment for many covariates that may
cause a genetic instrument to violate the IV assumptions, e.g. by association with a covariate that
confounds the exposure-outcome association. Furthermore, although the Finnish population is
relatively homogeneous, MR is so sensitive to population stratification that the latter is still a
concern if not accounted for. As a result, the approach needed to be able to adjust for covariates,
including principal components.
We chose penalized regression as a way to simultaneously adjust for possible
confounders, construct a polygenic score, and, in the case of the L1 penalty, choose the
predictive genotypes. Possibly assumption-violating covariates were included in the genotype
matrix but excluded from the penalty so that the fitted regression coefficients reflect only those
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effects not explained by the covariates. The final result was a one-sample MR analysis with a
weighted allele score as the instrument and weights determined by penalized regression. This
was performed in parallel using the L1 and L2 penalty, and the results were meta-analyzed.

3.6 My Role
As discussed in Section 3.1, Aim 2 originated from Lei Chen’s work studying the association
between metS and MT-CN. She led the SV GWAS analyses in which this association was
initially discovered, the measurement of MT-CN from Finnish WGS and WES data, and the tests
for association between MT-CN and most cardiometabolic traits. I led the remaining analyses,
including heritability estimation, common and rare variant GWAS, Mendelian randomization,
and the replication and interpretation experiments using data from the UK Biobank. A notable
exception is the regression analysis for HOMA-IR and Matsuda ISI shown in Table 3.1, which
were performed by Jagadish Vangipurapu. The Mendelian randomization strategy described in
Section 3.5.4 was developed in conjunction with Ryan Christ, a postdoctoral researcher in our
group, as was the strategy for analyzing UK Biobank data, although I performed both analyses
myself. The samples were provided by the FinMetSeq consortium.
What follows in Section 3.7 is a version of a manuscript describing the work of
addressing Aims 2a, 2b, and 2c. As of the writing of this dissertation, the manuscript is under
consideration at a journal, but a version of this study is available as a preprint166. I am the first
author on this work.
NOTE: Several Tables are too large to include in the current work. In these cases, these
Tables are available by accessing the preprint166. These Tables are referred to as Supplementary
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Tables in Section 3.7 and each time one is referenced, it is accompanied by its corresponding
Table number in the preprint.

3.7 Mitochondrial Genome Copy Number Measured by
DNA Sequencing in Human Blood is Strongly Associated
with Metabolic Traits via Cell-type Composition Differences
3.7.1 Abstract
Mitochondrial genome copy number (MT-CN) varies among humans and across tissues and is
highly heritable, but its causes and consequences are not well understood. When measured by
bulk DNA sequencing in blood, MT-CN may reflect a combination of the number of
mitochondria per cell and cell type composition. Here, we studied MT-CN variation in bloodderived DNA from 19,184 Finnish individuals using a combination of genome (N = 4,163) and
exome sequencing (N = 19,034) data as well as imputed genotypes (N = 17,718). We identified
two loci significantly associated with MT-CN variation: a common variant at the MYB-HBS1L
locus (P = 1.6×10-8), which has previously been associated with numerous hematological
parameters; and a burden of rare variants in the TMBIM1 gene (P = 3.0×10-8), which has been
reported to protect against non-alcoholic fatty liver disease. We also found that MT-CN is
strongly associated with insulin levels (P = 2.0×10-21) and other metabolic syndrome (metS)
related traits. Using a Mendelian randomization framework, we show evidence that MT-CN
measured in blood is causally related to insulin levels. We then applied an MT-CN polygenic
risk score (PRS) derived from Finnish data to the UK Biobank, where the association between
the PRS and metS traits was replicated. Adjusting for cell counts largely eliminated these signals,
suggesting that MT-CN affects metS via cell type composition. These results suggest that
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measurements of MT-CN in blood-derived DNA partially reflect differences in cell-type
composition and that these differences are causally linked to insulin and related traits.

3.7.2 Introduction
There are many reported links between mitochondrial content and cardiometabolic phenotypes in
various tissues, including adipose103,111,112, liver111,113,114, skeletal muscle100,109,111,117,119,132, and
blood96,101,102,108,123,125,167. Traits associated with mitochondrial (MT) content include coronary
heart disease (CHD), type 2 diabetes, and metabolic syndrome traits such as insulin
sensitivity/resistance, obesity, and blood triglycerides. However, these studies have generally
been limited by small sample sizes and low statistical power. This, in addition to the use of
heterogeneous mitochondrial quantification methods 95, has led to inconsistencies in the literature
about the strength and directions of effect between mitochondrial content and metabolic
syndrome (metS) traits. In one large WGS study of mitochondrial genome copy number (MTCN) in 2,077 Sardinians, Ding et al. estimated the heritability of MT-CN at 54% and detected
significant associations between MT-CN and both waist circumference and waist-hip ratio, but
found no association with body mass index (BMI)96. Another large study (N = 5,150) found
virtually no evidence of association between qPCR-measured MT-CN and any of several
cardiometabolic phenotypes107. The only exception was an inverse association with insulin that
was identified in one cohort but did not survive meta-analysis across cohorts. However, a study
of 21,870 individuals from 3 cohorts showed a significant inverse relationship between MT-CN
(measured by microarray probe intensities in two cohorts and qPCR in the third) and incident
cardiovascular disease104.
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Although variations in MT-CN measured from whole blood can in principle be attributed
to either variability of MT copy number within cells or the cell type composition of the blood
(given that different cell types have varying MT content168–170), the literature on this subject is
inconclusive. Using CpG methylation data, a large (N = 11,443), low-coverage (1.7x autosomal;
102x mitochondrial) sequencing study of the link between MT-CN and major depressive
disorder using buccal DNA from Chinese women concluded that variability of MT-CN from
buccal swabs was not due to differences in cell type composition110. However, this study did not
do a similar experiment in blood. Two small (N = 756 and N = 400) studies identified an
association between MT content and CHD that they attributed to variable MT-CN within
leukocytes, but they did not directly investigate the possibility of cell type composition being the
true driver of the association101,102. For brevity, we will use the term “MT-CN” to refer to the
underlying phenotype reflected by measuring this quantity for the remainder of this work, with
these caveats.
While several studies have found that peripheral blood MT content is heritable, only a
small number of MT-CN associated loci have been identified90,98,99. In one of these studies,
Curran et al. used linkage analysis in Mexican Americans to find an MT-CN associated locus
near a marker previously associated with triglyceride levels98,171,172, providing further indirect
evidence for the link between MT-CN and metabolic syndrome.
Here, we take advantage of large-scale genome, exome, and array genotype data to
investigate the causes and effects of MT-CN in a large, deeply phenotyped Finnish cohort. Our
results reveal novel links with metabolic syndrome and provide evidence supporting a causal role
for MT-CN.
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3.7.3 Methods
Genotype and Phenotype Data
Whole genome sequencing (WGS) was performed on a cohort of 4,163 samples comprising
3,074 male samples from the METSIM study35 and 1,089 male and female samples from the
FINRISK study36. Genomic DNA was fragmented on the Covaris LE220 instrument targeting
375 bp inserts. Automated Illumina libraries were constructed with the TruSeq PCR-free
(Illumina) or KAPA Hyper PCR-free library prep kit (KAPA Biosystems/Roche) on the
SciClone NGS platform (Perkin Elmer). The fragmented genomic DNA was size-selected on the
SciClone instrument with AMPure XP beads to tighten the distribution of fragmented DNA to
ensure the average insert of the libraries was 350-375 bp. We followed the manufacturer’s
protocol as provided by Perkin Elmer, with the following exception: post ligation, the libraries
were purified twice with a 0.7x AMPure bead/sample ratio to eliminate any residual adaptors
present. An aliquot of the final libraries was diluted 1:20 and quantitated on the Caliper GX
instrument (Perkin Elmer). The concentration of each library was accurately determined through
qPCR utilizing the KAPA library Quantification Kit according to the manufacturer's protocol
(KAPA Biosystems/Roche) to produce cluster counts appropriate for the Illumina HiSeqX
instrument. Libraries were pooled and run over a few lanes of the HiSeq X to ensure the libraries
within the pool were equally balanced. The final pool of balanced libraries was loaded over the
remaining number of HiSeq X lanes to achieve the desired coverage for this project. 2x150
paired end sequence data were demultiplexed using a single index, which was a restriction on the
HiSeqX instrument at this time. A minimum of 19.5x coverage was achieved per sample.
The quality of the aligned sequence data was assessed using metrics generated by
Picard173 v2.4.1, Samtools174 v1.3.1 and VerifyBamID175 v1.1.3. Based on the output files from
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Picard, the following alignment statistics were collected for review: PF_MISMATCH_RATE,
PF_READS, PF_ALIGNED_BASES, PCT_ADAPTER, PCT_CHIMERAS,
PCT_PF_READS_ALIGNED, PCT_READS_ALIGNED_IN_PAIRS,
PF_HQ_ALIGNED_BASES, PF_HQ_ALIGNED_Q20_BASES, PF_HQ_ALIGNED_READS,
MEAN_INSERT_SIZE, STANDARD_DEVIATION, MEDIAN_INSERT_SIZE,
TOTAL_READS, PCT_10x, and PCT_20x. Alignment rate was calculated as
PF_READS_ALIGNED/TOTAL_READS. The formula for haploid coverage was as follows:
1−𝑃𝐶𝑇_𝐸𝑋𝐶_𝐷𝑈𝑃𝐸

𝐻𝑎𝑝𝑙𝑜𝑖𝑑 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒 = 𝑀𝐸𝐴𝑁_𝐶𝑂𝑉𝐸𝑅𝐴𝐺𝐸 × 1 − 𝑃𝐶𝑇_𝐸𝑋𝐶_𝑇𝑂𝑇𝐴𝐿. From the Samtools output,
inter-chromosomal rate was calculated as:

𝑟𝑒𝑎𝑑𝑠_𝑚𝑎𝑝𝑝𝑒𝑑_𝑖𝑛_𝑖𝑛𝑡𝑒𝑟𝑐ℎ𝑟𝑜𝑚𝑜𝑠𝑜𝑚𝑎𝑙_𝑝𝑎𝑖𝑟𝑠
𝑟𝑒𝑎𝑑𝑠_𝑚𝑎𝑝𝑝𝑒𝑑_𝑖𝑛_𝑝𝑎𝑖𝑟

and discordant

rate was calculated as: 𝑟𝑒𝑎𝑑𝑠_𝑚𝑎𝑝𝑝𝑒𝑑_𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 −
𝑟𝑒𝑎𝑑𝑠_𝑚𝑎𝑝𝑝𝑒𝑑_𝑖𝑛_𝑝𝑟𝑜𝑝𝑒𝑟_𝑝𝑎𝑖𝑟𝑠_𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒.
Properly paired percentage (reads_mapped_in_proper_pairs_percentage) and singleton
percentage (reads_mapped_as_singleton_percentage) were also reviewed. From VerifyBamID,
the Freemix value was reviewed.
The metrics for judgement of passing data quality were:
FIRST_OF_PAIR_MISMATCH_RATE < .05, SECOND_OF_PAIR_MISMATCH_RATE <
0.05, haploid coverage ≥ 19.5, interchromosomal rate < .05, and discordant rate < 5. All of the
above metrics must have been met in order for the sample to be assigned as QC pass. If a sample
did not meet the passing criteria, the following failure analysis was performed: a) If the Freemix
score was at least 0.05, the sample or the library was considered contaminated, and both the
library and the sample were abandoned; b) if the discordant rate was over 5 and/or the interchromosomal rate was over 0.05, the quality of DNA was considered poor and the sample was
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removed from the sequencing pipeline; and c) in the case of a) and b), the collaborator was
contacted to determine if selection of a replacement sample from the same cohort was desired or
feasible.
Separately, whole exome sequencing (WES) data (N = 19,034), genotyping array data (N
= 17,718) imputed using the Haplotype Reference Consortium panel41 v1.1, and transformed,
normalized quantitative cardiometabolic trait data were obtained from an earlier study37.
FINRISK array data came in nine genotyping batches, two of which were excluded from the
present study due to small sample size. The traits, normalization and transformation procedures,
and sample sizes are described in a previous publication37. The WES and imputed sample sets
contained 4,013 and 3,929 of the 4,163 WGS samples included in the present study, respectively.
All participants in both the METSIM and FINRISK studies provided informed consent,
and study protocols were approved by the Ethics Committees at participating institutions
(National Public Health Institute of Finland; Hospital District of Helsinki and Uusimaa; Hospital
District of Northern Savo). All relevant ethics committees approved this study.
WGS Callset Generation and Quality Control
Single nucleotide polymorphisms (SNPs) and small insertions and deletions were called from the
full set of 4,163 samples using GATK80 v3.5. GVCFs containing SNVs and Indels from GATK
HaplotypeCaller (-ERC GVCF -GQB 5 -GQB 20 -GQB 60 -variant_index_type
LINEAR -variant_index_parameter 128000) were first processed to ensure no
GVCF blocks crossed boundaries every 1 Mb (CombineGVCFs; -breakBandsAtMultiplesOf 1000000). The resulting GVCFs were then processed in 10
Mb shards across each chromosome. Each shard was combined (CombineGVCFs), genotyped
(GenotypeGVCFs; -stand_call_conf 30 -stand_emit_conf 0), hard filtered to
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remove alternate alleles uncalled in any individual removed (SelectVariants; -removeUnusedAlternates), and hard filtered to remove lines solely reporting symbolic
deletions in parallel. All shards were jointly recalibrated (VariantRecalibrator) and then
individually filtered (ApplyRecalibration) based on the recalibration results. All of the above
methods were performed using GATK v3.5. SNP variant recalibration was performed using the
following options to VariantRecalibrator and all resources were drawn from the GATK hg38
resource bundle (v0):
-mode SNP
-resource:hapmap,known=false,training=true,truth=true,prior=15.0
-resource:omni,known=false,training=true,truth=true,prior=12.0
-resource:1000G,known=false,training=true,truth=false,prior=10.0
-resource:dbsnp,known=true,training=false,truth=false,prior=2.0
-an QD -an DP -an FS -an MQRankSum -an ReadPosRankSum
-tranche 100.0 -tranche 99.9 -tranche 99.0 -tranche 90.0

Indel variant recalibration was performed using the following options to VariantRecalibrator
(with the same resource bundle as with SNPs):
-mode INDEL
-resource:mills,known=true,training=true,truth=true,prior=12.0
-an DP -an FS -an MQRankSum -an ReadPosRankSum
--maxGaussians 4
-tranche 100.0 -tranche 99.9 -tranche 99.0 -tranche 90.0

When applying the variant recalibration the following options were used:
For SNPs: --ts_filter_level 99.0
For Indels: --ts_filter_level 99.0
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Following SNP and INDEL variant recalibration, multiallelic variants were decomposed
and normalized with vt81 v0.5. Duplicate variants and variants with symbolic alleles were
subsequently removed. The bottom tranche of variants identified by GATK’s Variant Quality
Score Recalibration tool and variants with missingness greater than 2% were removed as well,
although variants with allele balance between 0.3 and 0.7 were rescued. Variants with HardyWeinberg equilibrium (on a second-degree unrelated subset of 3,969 individuals, as determined
by KING176) P value less than 10-6 and those with allele balance less than 0.3 or greater than 0.7
were also removed.
Further sample-level quality control was undertaken on this dataset; 13 samples were
identified for exclusion because of singleton counts that were at least eight median absolute
deviations away from the median. Separately, 12 sex-discordant samples were flagged using
plink --check-sex, and after examining chromosome Y missingness and F coefficient
values for these samples, only the one that clearly differed from its reported sex was marked for
exclusion. No samples were excluded based on missingness fraction or the first five principal
components. In total, 14 samples were excluded from the heritability, GWAS, and Mendelian
randomization analyses; the other analyses were performed without exclusion of these samples.
As a result, the former analyses were performed with N = 4,149 while the latter had N = 4,163.
Mitochondrial Genome Copy Number Estimation
We estimated mitochondrial genome copy number (MT-CN) from both WGS and WES data. In
WGS data, we used BEDTools177 to calculate per-base coverage on the mitochondrial genome
from the latest available 4,163 WGS CRAM files. MT-CN was then calculated by normalizing
the mean coverage of the mitochondrial genome to the "haploid coverage" of the autosomes as
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calculated by Picard173. The result was then doubled to account for the diploidy of the autosomal
genome. This normalization is summarized by the following equation:
𝑚𝑒𝑎𝑛 𝑚𝑡𝐷𝑁𝐴 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒

𝑀𝑇_𝐶𝑁𝑊𝐺𝑆 = 2 × ℎ𝑎𝑝𝑙𝑜𝑖𝑑 𝑎𝑢𝑡𝑜𝑠𝑜𝑚𝑎𝑙 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒 .
The output from the above equation served as the raw measurement of per sample MTCN. To reduce batch effects, we separated the 4,163 samples into three groups: METSIM,
FINRISK collected in 1992 or 1997, and FINRISK collected in 2002 or 2007 (the FINRISK
batching decisions were made based on the means shown in Figure 3.5). Within each cohort, the
raw estimates were regressed on age, age2 and sex (FINRISK only) and the residuals were
inverse-normal transformed. We combined the three batches of normalized MT-CN values and
inverse-normal transformed the combined values for downstream analysis.
We used a similar procedure to estimate MT-CN from WES data, with mean autosomal
coverage estimates taken from XHMM178. However, as mitochondrial genomic coverage was
nonuniform due to the use of hybrid capture probes, mean mtDNA coverage was not an obvious
choice of metric for MT-CN estimation (Figure 3.6). To summarize this nonuniform
mitochondrial genomic coverage into a single number, we tried taking the mean and the
maximum depth of reads that aligned to the mitochondrial chromosome; the resulting values
were then processed in the same way as the WGS-estimated values. We evaluated the
approaches by measuring the R2 between WGS-estimated and WES-estimated MT-CN in the
4,013 samples for which both data types were available (Figure 3.7). While R2 was fairly high
using both approaches, the maximum coverage method was ultimately selected for use as it
yielded a higher R2 (0.445 vs 0.380). As a result, the WES MT-CN estimate was calculated as
follows: 𝑀𝑇_𝐶𝑁𝑊𝐸𝑆 = 2 ×

𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑚𝑡𝐷𝑁𝐴 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒
𝑚𝑒𝑎𝑛 ℎ𝑎𝑝𝑙𝑜𝑖𝑑 𝑎𝑢𝑡𝑜𝑠𝑜𝑚𝑎𝑙 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒
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Mitochondrial Haplogroup Estimation
We assigned mitochondrial haplogroups using HaploGrep179 v1.0. Mitochondrial SNP/indel
variants were genotyped using GATK GenotypeGVCFs, and a customized filter based on allele
balance was applied to the combined callset. HaploGrep was then used to call mitochondrial
haplotypes for each individual. We adjusted for major haplogroups in the same linear regressions
of metabolic traits onto MT-CN (see Section 3.7.4) and calculated the summary statistics from a
permutation test as implemented in the R package lmPerm
(https://github.com/mtorchiano/lmPerm).
Heritability Analysis
To estimate heritability of MT-CN, a genomic relatedness-based restricted maximum-likelihood
(GREML) method was used as implemented in GCTA180. The original GREML181 method was
used first, followed by GREML-LDMS182 to account for biases arising from differences in minor
allele frequency (MAF) spectrum or linkage disequilibrium (LD) properties between the
genotyped variants and the true causal variants183. For both analyses, MT-CN values were
normalized and residualized for sex, age, and age2 as described above. Heritability estimation
was performed jointly and separately for METSIM and FINRISK samples using WGS and
imputed array genotypes. In all cases, a minimum MAF threshold of 1% was applied. Beyond
those covariates already adjusted for in the normalization process, sensitivity analyses were
performed on imputed array data to determine whether heritability estimates were sensitive to
inclusion of covariates. In these experiments, either cohort or FINRISK genotyping array batch
were included as fixed-effect covariates in joint analyses of imputed array data; in neither case
was the final heritability estimate significantly affected (h2 = 0.09, SE = 0.02 in both cases). In
GREML-LDMS, genotypes were split into four SNP-based LD score quartiles and two MAF
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bins (1% > MAF > 5% and MAF > 5%), and genetic relatedness matrices (GRMs) were
estimated separately for each of the eight combinations. The GREML algorithm was then run on
all eight GRMs simultaneously using the first ten principal components (PCs) of the genotype
matrix (as calculated by smartPCA v13050; https://github.com/DReichLab/EIG) as fixed
covariates182. The use of GREML-LDMS over GREML also did not affect estimated heritability
values (Table 3.2), suggesting that the properties of the causal variants for this trait do not lead
to significant biases when using the standard GREML approach.
We observed that WGS heritability estimates decrease when analyzing FINRISK and
METSIM data together compared to analysis of METSIM alone (Table 3.3) (note that
FINRISK-only heritability estimates are not reliable as they have large standard errors resulting
from the small number of FINRISK samples sequenced). One potential explanation for this is
that there exists substantial heterogeneity across FINRISK survey years (Figure 3.5), and
between the FINRISK and METSIM cohorts, with respect to the reliability with which mtDNA
was captured (likely due to different DNA preparation protocols).
Genome-wide Association Analyses
Genome-wide association studies (GWAS) were performed using the same normalized
phenotype used in heritability analyses. Single-variant GWAS were conducted using EMMAX184
as implemented in EPACTS (https://genome.sph.umich.edu/wiki/EPACTS). Kinship matrices
required by EMMAX were generated by EPACTS; kinship matrices for WGS GWAS were
generated from WGS data, while those for WES and imputed array based GWAS were generated
from WES data. A P value threshold of 5×10-8 was used for the WGS and imputed array GWAS
while 5×10-7 was used for significance in the WES GWAS. Single-variant association analyses
of WGS and WES data did not include any covariates in the EMMAX model, although all
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association analyses were performed using MT-CN values that adjusted for age, age2, sex, and
cohort (see “Mitochondrial Genome Copy Number Estimation”). All association tests labeled
“joint” were performed on METSIM and FINRISK cohorts together; in one case, a randomeffects meta-analysis was performed using individual-cohort summary statistics and the R
package meta185.
Gene-based variant aggregation studies (RVAS) were done using a mixed-model version
of SKAT-O186 as implemented in EPACTS. Variants with CADD66 score greater than 20 and
minor allele frequency less than 1% were grouped into genes as annotated by VEP 187 (which by
default annotates a variant with a gene name if the gene falls within 5 kb of that gene). For genebased RVAS, Bonferroni-corrected genome-wide significance thresholds varied slightly due to
differing the number of genes with at least two variants meeting the above criteria in each test,
but were approximately 2×10-6 in all cases.
Mendelian Randomization
To assess the evidence for a causal relationship between mitochondrial genome copy number and
fasting serum insulin levels, the METSIM cohort alone was used due to its homogeneity of sex,
collection procedures, and location. A penalized regression based, multiple variant Mendelian
randomization (MR) approach was employed to enforce the necessary assumptions of MR.
While some MR studies have tested one or more assumptions post hoc, to our knowledge, there
is no published method that tries to enforce these assumptions during the process of building a
genetic instrument from multiple variants in the absence of a large set of known genotypeexposure associations. In our formulation (Figure 3.8A), X, the natural log of MT-CN (adjusted
for nuclear genomic coverage but not for age, age2, or sex), and a genotype matrix G were used
to build a genetic instrument Z, which was then tested against Y, the natural log of fasting serum
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insulin. The goal of the MR approach was to use a large number of common variants to build a
genetic instrument Z that satisfies the three assumptions of MR151:
1. Association of Z with X
2. Independence of Z from any variables U confounding the relationship between X and Y
3. Independence of Z and Y given X and U
To attempt to build a genetic instrument satisfying assumptions 2 and 3, the deep
METSIM phenotype data were leveraged. A matrix W was constructed using the 75 measured
traits and first 20 PCs of the genotype matrix (including a third-degree polynomial basis for PC
1). From these variables, covariates that could violate one of these two assumptions were chosen
by selecting columns of W associated with X or Y (Figure 3.8B). These columns were selected
using two successive LASSO feature selection procedures. First, a set A of covariates associated
with Y was chosen by using LASSO to regress Y onto W. In this regression, age and the thirddegree polynomial basis for PC 1 were left unpenalized to ensure that A contains these
covariates. The shrinkage parameter was chosen by tenfold cross-validation as the largest value
giving a mean squared error (MSE) within one standard error of the minimum observed MSE.
Next, the columns of W associated with X conditional on A were chosen using a similar LASSO
procedure in the regression of X onto W. In this step, however, the variables in set A were left
unpenalized in order to only capture associations that are conditionally independent of A. The
selected variables from this regression were designated set B.
The instrument was built using a penalized regression (using either an L1 or L2 penalty,
as implemented in glmnet188) of the form 𝑋 ∼ 𝐺 + 𝑊𝐴 + 𝑊𝐵 , where WA and WB are the
columns of W representing sets A and B, respectively, and G is a genotype matrix containing the
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alternate allele dosage (missing alleles are replaced with their MAF, similarly to PLINK 189) of all
variants with MAF greater than 1% and marginal GWAS P value below 0.01. As X was the
target vector for this regression, assumption 1 of MR was trivial. In the penalized regression, WA
and WB were unpenalized in an effort to orthogonalize the regression coefficients of the
genotypes to these covariates in an effort to enforce assumptions 2 and 3. glmnet was run with a
convergence threshold of 1×10-10 and maximum number of iterations of 200,000. To avoid the
overfitting that would result from calculating instrument values on the same samples on which
regression coefficients are learned145, the penalized regression model was fit on independent
subsets of the data as follows. Five models were fit, each by holding out a different 20% of
samples, such that the instrument value computed for each sample was calculated using the
regression coefficient vector learned without that sample. The vector of possible shrinkage
parameters λ for all five models was supplied as (103,102,…,10-13,10-14), and the λ value which
minimized the joint residual sum of squares of all five models was chosen for instrument
calculation.
Formally, we randomly partitioned the set of samples S with nonmissing insulin
measurements into five non-overlapping sets Sj for 𝑗 = {1, … ,5}. We denote set complements as
𝑆𝑗𝐶 = 𝑆 ∖ 𝑆𝑗 , such that each SjC contained 80% of the training samples. The instrument vector Zj
(−𝑗)

for each Sj was computed as follows: 𝑍𝑗 = 𝐺𝑗 × 𝛽𝐺

, where Zj is the instrument vector for Sj, Gj

is the genotype matrix of Sj, and βG(-j) is the vector of genotype regression coefficients from the
model described above, trained on SjC. The instrument values within each Sj were inverse ranknormalized using a Blom transformation190,191 before being concatenated across the values of j to
give the final instrument vector Z. Because samples with missing insulin values could not be
81

included in the causality test anyway, these samples were excluded from S but safely included in
the training sets of all five models. The instrument values of these samples were never calculated
or used in downstream analyses.
Often, the inclusion of unpenalized covariate sets A and B in the instrument-building
regression was not sufficient to completely orthogonalize Z to these covariates (see below). As a
result, the test for association between Z and Y was performed conditional on a set of potentially
assumption-violating covariates chosen using the newly constructed instrument Z in another
attempt to account for possible violations of MR assumptions in the causality test (Figure 3.8C).
To choose this set of covariates C, a final feature selection step was performed using LASSO
regression of Z on W with covariate set A excluded from the penalty. As in the previous feature
selection steps, the shrinkage parameter was chosen via tenfold cross-validation as the largest
value with MSE within one standard error of the minimum observed MSE. Once this set, D, of
covariates associated with Z was chosen, the covariates in W were partitioned into sets I, II, III,
and IV based on their membership in A and D (Figure 3.8). Formally, this partitioning was done
as follows:
𝐼 = 𝑊 \ (𝐴 ∪ 𝐷)
𝐼𝐼 = 𝐷 ∩ 𝐴𝐶
𝐼𝐼𝐼 = 𝐴 ∩ 𝐷𝐶
𝐼𝑉 = 𝐴 ∩ 𝐷,
where 𝐴𝐶 = 𝑊 \ 𝐴 and 𝐷𝐶 = 𝑊 \ 𝐷. Then, the test for causality came from the regression
coefficient of Z in the multiple regression 𝑌 ∼ 𝑍 + 𝐶, where C is the union of sets II, III, and IV
(colored blue in Figure 3.8C).
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To account for missing data in W, missing values were multiply imputed using regression
trees as implemented in the R package mice192 v3.4.0 (maxit=25). This imputation was
repeated 1,000 times in parallel, with each set of imputed values being carried through the entire
procedure described above. The resulting 1,000 computed instrument effect sizes and standard
errors were combined using Rubin’s method193 as implemented in the R package Amelia194
v1.7.5. The combined effect size and standard error were then tested for significance using a ttest with 998 degrees of freedom.
The above procedure was performed separately for METSIM samples with WGS data (N
= 3,034) and METSIM samples with only imputed array data (N = 6,774) using an L1 penalty in
the instrument-building regression, and again using an L2 penalty. Both sample sets were limited
to those for which relevant quantitative traits were available. An inverse-variance weighted
meta-analysis was performed across data sets for L1 and L2-penalized regression separately. The
resulting effect size and standard error were tested for significance using a Z test.
To ensure that our results were not driven by outlier samples, we removed outliers in two
stages. Before the MR analyses, we used principal components analysis (PCA), Mahalanobis
distance, and multi-trait extreme outlier identification to remove 5 WGS samples and 15 imputed
array samples based on quantitative trait data. We also removed high leverage, high residual
outliers from the causality test regression (see below) post hoc and recomputed the instrument
effect sizes to ensure that there was no significant change in the results. In each of the 1,000
multiple imputation runs, among the samples with standardized residual greater than 1, the top
10 samples by leverage were recorded. Any sample that was recorded in this way in at least one
run was then excluded from the re-analysis as a post hoc outlier. The results of this additional
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analysis showed only very small differences in effect estimates, and their interpretation remained
the same (Table 3.4). Thus, we concluded that our causal inference results were not driven by
outlier samples.
One caveat of this method is that, as mentioned above, exclusion of sets A and B from the
regression penalty did not perfectly orthogonalize the resulting instrument from these variables
in practice (Figure 3.9). Reasons for this may include relatively low levels of shrinkage in the
instrument-building regression or higher order associations between MT-CN and the
confounding variables. However, our method still represents an improvement over the current
standard, which is not to adjust for these covariates at all. Another caveat is that it is impossible
to determine the perfect set of covariates for which adjustment is appropriate. Lack of adjustment
for truly confounding variables can result in an instrument which does not satisfy MR
assumptions 2 and/or 3, yielding a biased effect estimate. Conversely, unnecessary adjustment
for certain variables can also result in biases. For example, adjusting for an intermediate
phenotype that truly lies along the path from Z to X to Y can cause a false negative signal,
making the causality test overly conservative. Alternatively, adjusting for some variables can
result in collider biases195. That is, if both Z and Y are causal for a confounder U, then adjusting
for U can induce a dependency between Z and Y (Figure 3.10) that did not previously exist.
We note that a known source of bias in MR studies is the selection of samples based on
case-control status for a related disease150. While METSIM is a population-based study, samples
were selected for WGS based on cardiovascular disease case-control status so as to enrich the
sequenced samples for cases. This has the potential to bias a MR experiment if both the exposure
and the outcome are associated with the disease, which is certainly possible. However, in our
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design, all of the METSIM samples not chosen for WGS were tested in the imputed array
experiment. The consistency of effect estimates between the WGS and imputed array samples
both in the L1 and L2 penalty cases (Figure 3.8D) suggests that there is little to no bias arising
from sample selection in this experiment.
Calculation and Testing of Polygenic Risk Score in the UK Biobank
To search for associations between MT-CN and other phenotypes, the genetic instrument
calculated in Finnish imputed array data was computed and treated as a polygenic risk score
(PRS) in a relatively homogenous subset of 357,656 UK Biobank samples identified by a
previous study196. We calculated ̅̅̅
𝛽𝐺 , the average of the five values of βG(-j) across all 1,000
multiple imputation runs using an L2 penalty and imputed array data – the L2 penalty was
chosen because it performed better than the L1 on both METSIM data types, and the imputed
array data set was chosen due to its larger sample size than the WGS set (Figure 3.8D). Next, to
keep the procedure as consistent as possible with the imputation protocol used for METSIM
– which used haploid dosage values to call imputed genotypes37 – we called imputed genotypes
using the expected alternate allele dosage from the UK Biobank by setting thresholds of 0.5 and
1.5. Using the resulting imputed variant calls, we calculated our PRS as 𝑍̃ = ̅̅̅
𝛽𝐺 × 𝐺̃ , where 𝐺̃ is
the UK Biobank genotype dosage matrix constructed in the same way as G in METSIM.
To test for associations with MT-CN PRS in the UK Biobank, we employed two
approaches: a hypothesis-driven analysis targeted to the phenotypes associated with MT-CN in
the Finnish data as well as a hypothesis-free screen of all the phenotypes available to us.
In the targeted analysis, we used our genetic instrument from the MR experiment as a
PRS for MT-CN in our chosen subset of the UK Biobank and tested for associations with several
blood cell count and metabolic syndrome traits. Given the association of MT-CN with rs9389268
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(see Section 3.7.4), we selected as cell count traits total leukocyte count as well as lymphocyte,
neutrophil, monocyte, and platelet counts for testing (because lymphocyte count was not readily
available, it was calculated as the product of leukocyte count and lymphocyte percentage). We
did not include basophils and eosinophils in this analysis considering that they comprise a small
minority of white blood cells and are unlikely to affect MT-CN measured from whole blood. All
cell count traits were log-transformed and standardized separately by sex.
We took several steps to eliminate outlier samples in the dataset. Through three iterations
of PCA on the cell count matrix and subsequent outlier removal, we removed 1,637 outlier
samples. We then fit null linear models of the form 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 ∼ 𝑎𝑔𝑒 + 𝑎𝑔𝑒 2 + 𝑠𝑒𝑥 +
𝑎𝑔𝑒: 𝑠𝑒𝑥 + 𝑎𝑔𝑒 2 : 𝑠𝑒𝑥 + 𝑃𝐶𝑠 (the first 20 PCs were included) for each cell count trait and
subsequently removed samples with either large residuals or high leverage and moderate
residuals in at least one model (following the example of the Neale group196). Through two
iterations of null model fitting and outlier removal, we removed 7 additional samples based on
null model fit. Tests of association between cell counts and MT-CN PRS were based on the PRS
regression coefficient in linear models of the form 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 ∼ 𝑃𝑅𝑆 + 𝑎𝑔𝑒 + 𝑎𝑔𝑒 2 + 𝑠𝑒𝑥 +
𝑎𝑔𝑒: 𝑠𝑒𝑥 + 𝑎𝑔𝑒 2 : 𝑠𝑒𝑥 + 𝑃𝐶𝑠.
We repeated this process for those cardiometabolic traits found to be suggestively
associated with MT-CN in the Finnish dataset (P < 10-6) that were also readily available in the
UK Biobank (Figure 3.3A, Supplementary Table 3.1/preprint Table S1); these phenotypes
were body mass index (BMI), fat mass, C-reactive protein, high-density lipoprotein, total
triglycerides, and weight. We also chose to include T2D status because of the lack of insulin
measurement in the UK Biobank. Except for T2D, a binary trait, all traits were log-transformed
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before further analysis (after removing 817 samples with negative values for T2D, representing
missing information). The above outlier removal steps were repeated for the cardiometabolic
traits after excluding the outliers already identified from the cell count data, with the only major
modification being the use of logistic regression for the T2D models. This process resulted in the
removal of 42 and 53 samples from PCA and null model fitting, respectively.
SKAT-O tests of association between TMBIM1 and the cell count traits identified above
were also performed. Similarly to the RVAS in Finnish data, variants within 5 kb of TMBIM1
with MAF < 1% and CADD v1.6 score > 20 were selected for inclusion in this analysis. Rather
than the mixed-model version of SKAT-O used in the Finnish data, standard SKAT-O was used
due to the lower expected level of cryptic relatedness in the UK Biobank population.
We also performed a hypothesis-free, phenome-wide screen of UK Biobank traits to
which we had access (Supplementary Table 3.2/preprint Table S10), to search for other
associations with MT-CN PRS. The statistical models used in this screen were of the same form
as those described above, both with and without adjustment for neutrophil and platelet counts. To
curate and transform phenotypes, we used an adapted version of PHESANT196,197. A few further
modifications were made to the pipeline, the most significant being the direct use of logistic
regression for testing categorical unordered variables, the inclusion of cancer phenotypes, and
the exclusion of sex-specific (or nearly sex-specific) categorical traits. The PHESANT pipeline
we used196 outputs continuous variables both in their raw form and after applying an inverse rank
normal transformation. For the sake of being conservative and robust to outliers, we chose to
interpret the results from the normalized continuous variables. To control false discovery rate,
we performed a Benjamini-Hochberg procedure with Storey correction as implemented in the R
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package qvalue198 v2.18.0 on the categorical and normalized continuous variables together. As a
secondary analysis, this same correction was applied to the categorical and raw continuous
variables together.

3.7.4 Results
Association of MT-CN with Metabolic Traits
We estimated MT-CN in 4,163 individuals from the METSIM and FINRISK studies based on
deep (>20x coverage) WGS data. We did so by measuring the mean coverage depth of reads
mapped to the mitochondrial genome in each sample, and normalizing it to the mean autosomal
coverage (see Section 3.7.3). We performed batch normalization separately for METSIM and for
two FINRISK batches separated by survey years (see Section 3.7.3). Each measurement was
adjusted for age, age2, and sex, then inverse rank normalized separately before combining across
batches. We tested the resulting MT-CN estimates for association with 137 quantitative traits that
were collected and normalized according to the procedures described previously 37. MT-CN was
strongly associated with fat mass (P = 4.48 x 10-16) and fasting serum insulin (P = 2.02 x 10-21),
as well as numerous additional quantitative traits, many related to metabolic syndrome (Figure
3.3A, Supplementary Table 3.1/preprint Table S1). Notably, BMI was significantly associated
with MT-CN, although Ding et al. did not find evidence of this association96. Since population
structure was a potential confounder in this analysis considering the presence of mtDNA
polymorphisms that might adversely affect short-read alignment, we included SNP-inferred
mitochondrial haplogroup as a covariate and reran the tests (Figure 3.3B). The association
signals retained significance even after this adjustment.
To understand the connection between MT-CN and more clinically relevant phenotypes,
we tested our MT-CN estimate against Matsuda ISI and disposition index (Table 3.1), which
88

measure insulin sensitivity and secretion, respectively, and were not included in the initial
screen. MT-CN was strongly associated with both insulin phenotypes. Notably, the Matsuda ISI
signals survived adjustment for fat mass percentage after excluding diabetic individuals, which
indicates that the association of peripheral blood MT-CN with insulin sensitivity was
independent of fat mass.
To test for this association signal in a larger cohort, we developed a method to estimate
mitochondrial genome copy number using 19,034 samples with whole exome sequencing (WES)
data from the METSIM and FINRISK studies that included most of the WGS samples37 (see
Section 3.7.3). R2 between WGS-based and WES-based estimates was 0.445 (Figure 3.7).
Consistent with the WGS-based analysis, WES-estimated MT-CN was significantly associated
with both fat mass and fasting serum insulin levels, even after removing the samples with WGS
data, with identical directions of effect (Table 3.5).
Anecdotally, it is interesting to note that these MT association signals can also be
detected using read-depth analysis of the nuclear genome (Figure 3.1; manuscript under
review86 - preprint doi: 10.1101/2020.12.13.422502), where reads derived from mtDNA align
erroneously to several nuclear loci based on homology between the MT genome and ancient
nuclear mitochondrial insertions. This result provides additional evidence for the reported trait
associations using an independent MT-CN estimation method, and indicates that these
homology-based signals need to be taken into account in future copy number variant association
studies.
Heritability Analysis
To assess the extent to which MT-CN is genetically determined, we estimated the heritability of
mitochondrial genome copy number using GREML (Table 3.3). We explored two different
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approaches available: (1) analysis of the 4,149 samples with WGS data that passed quality
control measures, where both nuclear genotypes and MT-CN are measured directly from the
WGS data, and (2) analysis of the set of 17,718 samples with imputed genotype array data,
where MT-CN is estimated from WES data. Of these, (1) benefited from more accurate
measurement of genotype and phenotype, whereas (2) had noisier measurements but benefited
from larger sample size. We focused primarily on the METSIM cohort, both because of the
homogeneity of this cohort (see Section 3.7.3) and because the number of FINRISK samples
with WGS data was small.
In the WGS analysis, the GREML-estimated heritability of MT-CN in METSIM was
31% - somewhat less than the 54% value reported in the only prior large-scale study of
peripheral blood MT-CN heritability, which was based on low-coverage WGS96. For
comparison, we used this same approach to estimate heritability of LDL in METSIM WGS data,
which yielded an estimate of 34% with a standard error of 7.9% (Table 3.2). This is broadly
consistent with prior work199,200, including analysis of the same Finnish sample set using distinct
methods37 (20.2% heritability). These results show that mitochondrial genome copy number is a
genetically determined trait with significant heritability, comparable to that of LDL and other
quantitative cardiometabolic traits37.
The analysis of imputed METSIM genotypes using WES-estimated MT-CN yielded an
estimated heritability of 11%, which is much lower than the WGS-based estimate (Table 3.3).
To understand this discrepancy, we repeated the GREML analysis with the other two
combinations of phenotype source (WGS vs. WES estimation) and genotype source (WGS vs.
imputed array). When using the WGS-measured phenotype, the estimated heritability decreased
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only slightly (31% to 27%) when switching from the WGS to imputed genotypes. This suggests
that the difference in genotyping method was not the main driver of the observed heritability
disparity between the WGS and imputed array datasets. Conversely, when analyzing the imputed
METSIM genotypes, switching from WGS-measured to WES-measured MT-CN resulted in a
large drop (27% to 11%) in estimated heritability. This suggests that the extra noise inherent in
WES-based MT-CN estimates was responsible for the reduction in the GREML-estimated
heritability despite the increased sample size of the imputed array dataset.
Identification of Genetic Factors Associated with MT-CN
Previous studies have identified three autosomal quantitative trait loci (QTL) reaching genomewide significance for MT-CN in other populations90,98. Another recent study identified two
putative QTLs with suggestive P values99. We conducted a single variant GWAS for MT-CN
(see Section 3.7.3); analysis of WGS (N = 4,149) and WES (N = 19,034) genotypes yielded no
variants exceeding the respective significance thresholds of 5×10-8 and 5×10-7 (Figure 3.11).
However, despite the increased noise in the WES-measured phenotype, GWAS of imputed array
genotypes from METSIM (N = 9,791) yielded two loci with genome-wide significant
associations, identified by lead markers rs2288464 and rs9389268 (Figure 3.12, Table 3.6). Of
the previously-reported MT-CN QTLs90,98,99, we observed an inconclusive signal at rs445 (P =
0.048) and a significant signal at rs709591 (P = 1.61×10-4), a locus associated with neutrophil
count201,202 (Table 3.7). No significant signal was observed at the other two single-variant QTLs
(Table 3.7) or the linkage peak identified by Curran et al. (Figure 3.13).
rs9389268 was the only marker that was strongly associated with MT-CN in the
METSIM analyses of both WGS and imputed array data (P = 3.24×10-8 and P = 1.26×10-10,
respectively). Although this variant was not significantly associated with MT-CN in FINRISK (P
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= 0.788 and P = 0.189 in WGS and imputed array data, respectively) or in a separate randomeffects meta-analysis of both cohorts (P = 0.115), the lack of signal in FINRISK is likely the
product of lower-quality MT-CN measurements in FINRISK, which displayed heterogeneity
across survey years (Figure 3.5). This variant is located in an intergenic region between the MYB
and HBS1L genes, is common across many populations, and is slightly more frequent in Finns
compared to non-Finnish Europeans (gnomAD v3 MAF 34.4% vs. 26.0%). MYB and HBS1L are
hematopoietic regulators203,204, and the region between them is known to be associated with
many hematological parameters including fetal hemoglobin levels, hematocrit, and erythrocyte,
platelet, and monocyte counts205–208. It has been suggested that these intergenic variants function
by disrupting MYB transcription factor binding and disrupting enhancer-promoter looping209.
Conditioning the METSIM-only imputed array GWAS on rs9399137 – a tag SNP shown to be
associated with many of these hematological parameters 207 – resulted in elimination of the
rs9389268 signal entirely (P = 0.408), suggesting that the haplotype responsible for the
association of rs9389268 with MT-CN in our data is the same one previously known to be
associated with hematological phenotypes.
This result is not surprising considering our approach for normalizing MT-CN. Because
our MT-CN estimate was based on the ratio of mtDNA coverage to nuclear DNA coverage,
changes in the cell type composition of blood could result in changes in our normalized
measurement if the underlying cell types have different average numbers of mitochondria. This
is especially true of platelets, which can contain mitochondria but not nuclei, and whose counts
are known to be associated with rs9399137.
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rs2288464 seemed to be a good candidate due to its location in the 3’ untranslated region
of MRPL34, which codes for a large subunit protein of the mitochondrial ribosome. While the
association signal at this marker was not observed in the WGS data (P = 0.0655), based on the
observed effect size of this variant in WES and imputed data as well as the number of WGS
datasets available, there was insufficient power (~0.5% at α = 5×10-7) to robustly detect this
association in the WGS data210.
We next performed rare variant association (RVAS) analyses using a mixed-model
version of SKAT-O186 to test for genes in which the presence of high-impact rare variants might
be associated with MT-CN levels (see Section 3.7.3; Figure 3.14, Table 3.8). Using WES data,
the only gene passing the Bonferroni-adjusted P value threshold of 2.16×10-6 was TMBIM1 (P =
2.96×10-8), a member of a gene family thought to regulate cell death pathways211. TMBIM1 has
been shown to be protective against non-alcoholic fatty liver disease (NAFLD), progression to
non-alcoholic steatohepatitis, and insulin resistance in mice and macaques 212. Interestingly, in
our analysis - in which a burden test was determined to be optimal by SKAT-O - rare, putatively
high-impact variants in TMBIM1 were associated with a higher MT-CN (Figure 3.14C). Higher
MT-CN was, in turn, associated with less severe metabolic syndrome, suggesting that TMBIM1
is actually a risk gene, not a protective one. Thus, the published function of TMBIM1 makes it a
strong candidate, although the direction of effect in our data disagreed with the direction
suggested by prior work in model organisms212.
Inference of Causality in the Association Between MT-CN and Insulin
To further understand the association between MT-CN and fasting serum insulin, we employed a
Mendelian randomization (MR) approach with MT-CN as the exposure and insulin as the
outcome. Using penalized regression, we leveraged our extensive phenotype data to build a
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genetic instrument from a large number of genetic variants and adjust for possible confounders
via a novel approach (see Section 3.7.3; Figure 3.8). We believe this approach to be more robust
to violations of key MR assumptions than other methods in situations where limited data are
available and few robust genotype-exposure associations are known. We restricted our analysis
to METSIM samples due to batch effects and inconsistencies in available quantitative trait data
observed across FINRISK survey years (Figure 3.5). The effect sizes of the instrument in the
causality test for insulin levels are shown in Figure 3.8D. We calculated our instrument using
either L1 or L2 regularization, and in both cases, the MT-CN instrument was not a significant
predictor (α = 0.05) of insulin when we constructed our instrument from WGS variants, but was
significant when the instrument was constructed from imputed array variants. This was likely
due to the larger sample size of the imputed array data set. However, the effect estimates were
remarkably similar across all four cases. As a result, inverse-variance weighted meta-analysis
across datasets yielded highly significant P values for both penalties. In summary, our analysis
provided evidence for a significant causal role for MT-CN in determining fasting serum insulin
levels that was robust to the choice of regression penalty when building the genetic instrument.
We note that this evidence for causality comes with some caveats (see Section 3.7.3).
Replication and Biological Interpretation
In principle, changes in MT-CN can be caused by changes in the number of mitochondrial
genome copies within cells or by changes in the blood cell type composition. Based on the
association with rs9389268 and the nuances of the normalization procedure described above, we
sought to test the hypothesis that our MT-CN measurement primarily reflects the cell type
composition of the blood rather than the number of mitochondria per cell. We used imputed
array genotype and phenotype data from the UK Biobank (N = 357,656) for this purpose213.
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We first tested cell counts from the UK Biobank (UKBB) against a polygenic risk score
(PRS) for MT-CN built using the genetic instrument from the Finnish data. Leukocyte,
neutrophil, and platelet counts were all significantly associated with MT-CN PRS (see Section
3.7.3, Table 3.9). However, adjusting for neutrophil counts in the leukocyte regression
eliminated the signal (PRS regression coefficient P = 0.839), suggesting that the leukocyte count
signal was driven by the effect of neutrophil count. We removed any high leverage, large
residual samples and repeated the neutrophil and platelet count regressions to ensure that this
result was robust to outliers and found no appreciable change in significance (Table 3.9). As a
result, we concluded that our MT-CN measurement was significantly associated with neutrophil
and platelet counts. Subsequent analyses were performed both with and without adjustment for
these variables, as described below.
We note that the effect directions of the associations of platelet counts with metS and
MT-CN PRS seem inconsistent at first glance, as platelet counts were positively correlated with
MT-CN PRS (Table 3.9) and metS (Table 3.10) while MT-CN and insulin (a proxy for metS)
were negatively correlated (Figure 3.3B). However, the FinMetSeq regression model in Figure
3.3B was not conditional on any other covariates (although age, age2, and sex were regressed out
of the MT-CN measurement prior to this analysis), while the UKBB models that gave rise to
Table 3.9 and Table 3.10 adjusted for many additional covariates, including 20 PCs and age-sex
interaction terms. As a result, the effect directions for the analyses in the two datasets are not
directly comparable.
We next tested for associations between MT-CN PRS and several cardiometabolic
phenotypes from the test in Figure 3.3A (see Section 3.7.3). With the exception of C-reactive
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protein, which showed no significant association, all tested phenotypes showed nominal
association with MT-CN PRS at α = 0.05, with total triglycerides and HDL being the only traits
surviving Bonferroni correction (Table 3.11). We interpret this as replication of the link between
mitochondrial genome copy number and metabolic syndrome in a large, independent data set.
To determine whether there was any association between MT-CN and metabolic
syndrome not mediated through cell counts, we repeated the tests of cardiometabolic trait
association with MT-CN PRS with adjustment for platelet and neutrophil counts. HDL was the
only trait with a nominal (α = 0.05) association with PRS under this adjustment, but this signal
was not strong enough to survive Bonferroni correction (Table 3.11). This suggests that the
associations we observed between MT-CN and metabolic traits arose simply because MT-CN is
a proxy for platelet and neutrophil count. This was supported by the fact that direct testing of
platelets and neutrophils against triglycerides, fat mass, and HDL yielded remarkably significant
associations, which survived post-hoc removal of high-leverage, high-residual outlier samples
(Table 3.10). This evidence for MT-CN as a proxy for platelet and neutrophil counts strongly
suggests that the causal relationship observed in the Mendelian randomization experiment (see
above) in fact represents a causative role for neutrophils and platelet counts in determining serum
insulin levels.
Given the strong observed associations between blood cell count phenotypes and MT-CN
PRS, we used these blood phenotypes to seek replication of the genetic associations detected in
Finnish data. Using imputed UKBB genotype data, we tested the expected alternate allele dosage
of both rs2288464 and rs9389268 against the same blood cell traits mentioned above, using
linear regression (Table 3.12; expected alternate allele dosage was calculated from genotype call
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probabilities as 𝐷𝑆 = 𝑃(0/1) + 2𝑃(1/1)). As expected given its known associations with
multiple hematological parameters (see above), rs9389268 showed strong associations with all
tested blood cell phenotypes. rs2288464 was not significantly associated with any of the five
phenotypes after correction for multiple testing, although a nominal association was detected
with total leukocyte count. This further strengthens our belief that rs9389268 is truly associated
with MT-CN through blood cell composition. We also tested TMBIM1 against the same blood
cell traits in UKBB using SKAT-O186, and found no significant associations (Table 3.12). This
may mean that TMBIM1 affects MT-CN through a mechanism other than altering blood cell type
composition, although more work is needed to confirm this.
As further evidence that MT-CN is a proxy for blood cell composition, we looked up
MT-CN association P values in METSIM for the top five neutrophil and platelet count QTLs
from the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.uk/gwas). Out of ten variants tested,
five had P < 0.05 in METSIM (Table 3.7). We note that three of these five were either near or
identical to known MT-CN loci (including rs9389268, the marker identified in this study).
rs25645, a variant reported to be highly associated with neutrophil count202, is only 2.5 kb away
from rs709591, a SNP with a reported suggestive association with MT-CN99 and a P value of
1.61×10-4 in our METSIM study. Moreover, rs11759553, a platelet-associated variant202, is 324
kb away from rs9389268, the lead marker for MT-CN in METSIM (rs11759553 P = 2.15×10-10
in METSIM). Finally, rs445 was reported as a lead marker for both MT-CN association90 and
platelet count202. rs445 has P = 0.048 for association with MT-CN in METSIM. While none of
the 10 known cell count-associated markers tested achieved significance beyond a Bonferroni
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threshold, the overlap between these variants and independently-measured MT-CN QTLs was
suggestive of a relationship between cell counts and whole blood-derived MT-CN.
Using UKBB data, we further sought to generate hypotheses for other phenotypic
associations with MT-CN. To this end, we performed a phenome-wide screen of MT-CN PRS
against all of the UKBB phenotypes available to us. To curate and transform these phenotypes,
we used a modified version of PHESANT196,197, which outputs all continuous variables in both
raw and inverse rank-normalized form. We chose to interpret the results from the normalized
continuous variables (Supplementary Table 3.3/preprint Table S5) to be conservative and
robust to outliers, although the results of the raw continuous variable analyses were similar
(Supplementary Table 3.4/preprint Table S6). No metabolic syndrome traits appeared among
the tested traits with q < 0.05. However, the tests for HDL cholesterol, self-reported heart attack,
and doctor-diagnosed heart attack did yield somewhat suggestive results (q = 0.123, 0.176, and
0.176, respectively). We also repeated this screen with adjustment for neutrophil and platelet
counts (Supplementary Table 3.5/preprint Table S7 and Supplementary Table 3.6/preprint
Table S8), resulting again in no metabolic syndrome phenotypes achieving q < 0.05. The
addition of neutrophil and platelet counts as covariates attenuated the suggestive signals for HDL
cholesterol, self-reported heart attack, and doctor-diagnosed heart attack (q = 0.284, 0.391, and
0.402, respectively).

3.7.5 Discussion
We have described one of the most well-powered studies to date of the genetic relationship
between MT-CN measurements in blood and cardiometabolic phenotypes. Our study is one of
very few of which we are aware to utilize WGS data, found to be the most reliable method for
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estimating MT-CN in a recent study95, for this purpose. Our data show highly significant
associations between blood-derived MT-CN measurements and several cardiometabolic traits,
particularly insulin and fat mass. We observed strong heritability of MT-CN (31%), on par with
other widely studied cardiometabolic traits such as LDL, and identified one single marker
association on a haplotype previously associated with several hematological parameters 205–208. A
previous study using qPCR to quantify MT-CN reported two sub-threshold QTLs99; of these
markers, only rs709591 replicated in our study (P = 1.61×10-4). We also report one gene with a
rare-variant association with MT-CN, TMBIM1, that has a known link to non-alcoholic fatty
liver disease212. More work is needed to replicate this genetic association.
Using a novel multiple-variant instrument building method, we report evidence from
Mendelian randomization supporting a causal role for MT-CN in metabolic syndrome. Further,
we used UK Biobank data to show that the link between MT-CN and metabolic syndrome
replicates in an independent data set using a polygenic risk score approach. Contrary to previous
claims that variability in the number of mitochondria per cell is responsible for CHD risk101, this
association is mediated by neutrophil and platelet counts.
One important question that our study cannot definitively resolve is the relative
contribution of intracellular mitochondrial abundance versus cell-type composition differences in
determining the measured MT-CN value. We identified a MT-CN association result at a known
QTL for cell type composition of blood205–208 (HBS1L-MYB), and we further replicated a prior
association at a different neutrophil-associated locus201,202 (rs709591). Together, these results
argue that cell type composition is an important component of this measurement. On the other
hand, two other significant associations from the Finnish dataset (rs2288464, TMBIM1) showed
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no effect on cell type composition in the UK Biobank. Future work in large cohorts with both
WGS and cell count data – which were not simultaneously measured in any samples in this study
– will be required to rigorously determine what blood-derived MT-CN primarily measures.
However, the results of our MR and UK Biobank analyses together suggest that MT-CN is
causally related to metabolic syndrome traits, and that this relationship is mediated by cell-type
composition differences.
There is prior evidence to support the role of inflammation – specifically via innate
immune cells such as neutrophils – in the etiology of type 2 diabetes (T2D) and insulin
resistance214–216, which suggests a plausible model by which peripheral blood neutrophil count
could influence metabolic syndrome. Nutrient excess and high fat diets are known to recruit
neutrophils into tissues, which then cause insulin resistance both by releasing TNF-⍺ and IL-6
and by upregulating cyclooxygenase214. This leads to increased LTB4 and subsequent
upregulation of NF-𝜅B, a central regulator of inflammation. Moreover, free fatty acids also cause
neutrophils to stay in tissues longer, resulting in persistent inflammation and leading to insulin
resistance214. While it is known that inflammation, and particularly neutrophils, play a role in
metabolic syndrome, our results strongly suggest that peripheral blood neutrophil count causally
contributes to this process and is associated with heritable genetic variation in the human
population. Our work supports the idea that targeting inflammation may be a fruitful avenue of
investigation in developing future therapeutics.
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dbGaP (accession numbers phs001579, phs000752, and phs000756). METSIM callsets from
WGS and imputed array data as well as MT-CN phenotype values will soon be available through
AnVIL. Imputed array GWAS summary statistics from METSIM and and WES SKAT-O
summary statistics from the joint dataset are freely available at
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https://wustl.box.com/s/7xfbmxq2r4kg8p8bfc7vpqlrmqvhm0lx. Genomic and phenotypic data
for the FINRISK cohort are obtainable through THL Biobank, the Finnish Institute for Health
and Welfare, Finland (https://thl.fi/en/web/thl-biobank).

3.8 Aim 2 Conclusion
The second Aim of this work is to interrogate the genetics of peripheral blood MT-CN and its
relationship to metabolic syndrome. A review of the existing literature is presented in Sections
3.2 and 3.3 detailing the state of the field with respect to MT-CN genetics and its relationship to
CVD and metS. While extensive, the literature on the latter subject is inconsistent on both the
existence and directions of effects between MT-CN and both CVD and metS. This is likely a
result of a lack of statistical power as well as the variety of distinct MT-CN quantification
methods that vary in their accuracy95. The lack of agreement on this subject justifies a large
study that uses the most accurate MT-CN quantification method available to bring clarity to the
field; the work presented in Section 3.7 fulfills this need. In Section 3.4, the relationship between
inflammation and metS is discussed, which is integral to the interpretation of the results of
Section 3.7, as MT-CN is found to largely be a proxy for inflammatory status, at least in its
association with metS. Section 3.5 introduces Mendelian randomization, explains its theoretical
basis, and addresses many practical strategies for applying this method. This discussion is
valuable as Section 3.7 introduces and applies a novel MR method that adjusts for possible
assumption-violating covariates while building a genetic instrument from multiple variants. This
represents an improvement over many previous studies which generally only test some or all of
the IV assumptions post hoc.
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The previous Section contains a large study of Finnish WGS, WES, and imputed
genotyping array data that addresses Aim 2 and its subaims. This work assesses heritability of
MT-CN and identifies several QTLs, including a novel gene. It also demonstrates a highly
significant association between MT-CN and many metS traits and uses the aforementioned MR
approach to show evidence that MT-CN is causal in its association with fasting serum insulin.
Finally, it replicates the association between MT-CN and metS in a large, independent dataset
and shows that it is largely mediated by platelets and neutrophils. The latter observation
implicates inflammatory status in this relationship, which is consistent with previous work on
this topic discussed in Section 3.4. In summary, the work in Section 3.7 addresses Aim 2 by
characterizing the genetics of peripheral blood MT-CN, using a novel modification to Mendelian
randomization to find evidence that MT-CN is causal in its relationship to metS, and using an
independent data set to replicate and interpret this association.
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3.9 Figures and Tables

Figure 3.1 Insulin association signal at chromosome 1 NumtS. Manhattan plot from an
analysis of copy number variation at nuclear mitochondrial insertion sites (NumtS) using
CNVnator read-depth measurements in 1 kb genomic windows, using an initial set of 2,049
samples from an earlier data freeze analyzed by Lei Chen86. For this reason, the P value does not
exactly match that shown in Figure 3.2. Shown at the bottom are two tracks from the UCSC
Genome Browser85. The black track represents an assembly gap upstream of the association
signal, and the blue track shows the location of the NumtS region where the association peak is
located.
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Figure 3.2 Associations with cardiometabolic traits using direct and indirect measurement
of MT-CN. Bar height represents the strength of association with each trait of MT-CN as
measured in three different ways. The top panel represents associations with fat mass and the
bottom panel represents associations with fasting serum insulin. The dashed red line indicates an
experiment-wide significance level of 3.53×10-9; this was calculated using Bonferroni correction
for 248,700 variable copy number window clusters and 57 independent traits (as estimated using
the method proposed by Li and Ji217).
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Figure 3.3 Cardiometabolic trait associations with MT-CN in WGS data. (A) Phenome-wide
association study of normalized MT-CN against 137 cardiometabolic traits in the 4,163 sample
data set. Traits are grouped into 17 categories, represented by the color of each bar. The top three
most significant traits are, in order: fasting serum insulin, C-reactive protein, and fat mass. Exact
P values and effect estimates, as calculated by EMMAX, are listed in Supplementary Table
3.1/preprint Table S1. (B) Association tests between normalized MT-CN and both fat mass and
fasting serum insulin using WGS data (N = 4,163). Results are shown for the EMMAX test and a
permutation test in which mitochondrial haplogroups were adjusted for.
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Figure 3.4 Directed acyclic graph illustrating the theory of Mendelian randomization.
Mendelian randomization (MR) depends on the choice of a genetic instrument Z, often a single
genotype, that is associated with an exposure X. The purpose of this method is to determine
whether X is causal for an outcome, Y, in the presence of confounders, U. Confounders may be
measured or unmeasured. Any path from Z to Y that does not go through X violates the exclusion
restriction (see Section 3.5.2).
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Figure 3.5 Raw WGS-based MT-CN estimate distributions for METSIM and all four
FINRISK surveys. Facet labels “1992”, “1997”, “2002”, and “2007” refer to individual
FINRISK survey years.
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Figure 3.6 Nonuniform WES coverage across the mitochondrial genome for four
representative samples.
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Figure 3.7 Comparison of two methods of summarizing nonuniform mitochondrial
coverage in WES into a single measurement. Both panels show the correlation with WGS
mean coverage for the 4,013 samples for which both WGS and WES data were available. (A)
shows the results of summarizing WES mitochondrial coverage using the maximum coverage
value across the mitochondrial chromosome while (B) shows the results of using the mean
mitochondrial coverage instead. R2 values are shown on each panel.
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Figure 3.8 Mendelian randomization approach and results. (A) Formulation of the
Mendelian randomization causality test. G represents genotypes, Z is a genetic instrument value
constructed from G, X represents ln(MT-CN), Y represents ln(Insulin), and U represents any
confounders of the association between X and Y. The arrow from X to Y is dashed to indicate that
although an association is known, the relationship is not known to be causal. In this formulation,
a significant association between Z and Y would provide evidence that X is casual for Y. (B)
Strategy for choosing variables to adjust for when building Z in order to enforce MR
assumptions. A represents those columns of covariate matrix W that are associated with Y
(represented by the solid line between A and Y) and B represents those columns of matrix W that
are associated with X conditional on A (represented by the solid line between B and X). Dashed
lines represent possible, but unproven associations. The penalized regression of X on G used to
build Z is adjusted for A and B (with no penalty) in an attempt to prevent any associations
between Z and either A or B (represented by the blue X’s). While an association between B and Y
is unlikely (represented by the dashed line between B and Y) because B is not contained in A, B
is still adjusted for in the penalized regression to be as conservative as possible. (C) Strategy for
choosing covariates to adjust for in the causality test of Y against Z in another attempt to reduce
the impact of any remaining associations between Z and assumption-violating variables.
Covariate sets I, II, III, and IV are defined by the presence of known first-order associations
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(represented by black lines) with Z and Y (see Section 3.7.3). Yellow lines represent relationships
where a first-order association is not known, but a higher-order association is possible. Covariate
sets II, III, and IV (colored blue) are adjusted for in the causality test because there is at least one
first order association linking them to Z and Y, so they risk violating MR assumptions 2 or 3. (D)
Results of Mendelian randomization test for causality of MT-CN on fasting serum insulin.
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Figure 3.9 Associations between Z and traits in set A in imputed data. P values computed
from linear regression using the output from a randomly chosen run of multiple imputation of
phenotype data. (A) and (C) show the marginal P values of the traits in set A from regressions of
Z onto each trait separately, while (B) and (D) show the P values from multiple regression of Z
onto all traits in set A. The instrument in (A) and (B) was computed using an L1 penalty, while
that in (C) and (D) was computed using an L2 penalty.
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Figure 3.10 Example of collider bias. If Z and Y are independently causal for a variable U, then
adjusting for U can induce an association between Z and Y that did not previously exist.
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Figure 3.11 Joint (METSIM and FINRISK) single-marker association tests with MT-CN in
WGS and WES data. (A) Manhattan plot and quantile-quantile (QQ) plot for an exome-wide
association test of normalized, WES-measured MT-CN using WES genotype data (N = 19,034).
The red line represents an exome-wide significance level of 5×10-7; no tested markers achieved
this level of significance. The QQ plot is separated by minor allele frequency bin, as indicated by
the colors and shapes of the points. (B) Manhattan plot and quantile-quantile (QQ) plot for a
genome-wide association test of normalized, WGS-measured MT-CN using WGS genotype data
(N = 4,149). The red line represents a genome-wide significance level of 5×10-8; no tested
markers achieved this level of significance. The QQ plot is separated by minor allele frequency
bin, as indicated by the colors and shapes of the points.
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Figure 3.12 Single-marker genetic associations with MT-CN in imputed array data. (A)
Manhattan plot for a genome-wide association test of normalized, WES-measured MT-CN using
imputed array genotype data from METSIM (N = 9,791). Two loci markers reached the genomewide significance of 5×10-8, identified by lead markers rs2288464 and rs9389268. (B) Quantilequantile (QQ) plot for the association test shown in (A). This plot is separated by minor allele
frequency bin, as indicated by the colors and shapes of the points. (C) Boxplot showing the
distributions of normalized WES-measured MT-CN in METSIM separated by the number of
rs9389268 alternate alleles as detected by imputed array genotyping (N = 9,791). The EMMAX
P value for this variant was 1.62×10-8 in imputed data.
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Figure 3.13 Single-marker association test results at chromosome 10 QTL identified by
Curran et al. Chromosome 10 Manhattan plot for association with WES-estimated MT-CN in
Finnish imputed array data from METSIM (N = 9,791). The blue highlighted region represents
the approximate location of the linkage peak reported for MT-CN by Curran et al.98. This region
is larger than the region reported by Curran et al. (~30 Mb vs. ~24 Mb) because the exact
coordinates of the 1-LOD support interval were not reported explicitly, so the genetic
coordinates were approximated from a figure and converted to physical coordinates using a
genetic map from HapMap Phase 2. Some error may also have been introduced due to differing
populations between the HapMap samples and the Mexican-American samples used by Curran et
al.
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Figure 3.14 Gene-based associations with MT-CN in WES data. (A) Manhattan plot and
quantile-quantile (QQ) plot for a gene-based rare variant association test of normalized, WESmeasured MT-CN using WES data from both METSIM and FINRISK (N = 19,034). The red line
represents a Bonferroni significance level of 2.164×10-6, as 23,105 genes were included in this
test. TMBIM1 is the only gene to reach significance at this level. (B) QQ plot for the test shown
in (A). This plot is separated by minor allele frequency bin, as indicated by the colors and shapes
of the points. (C) Boxplot showing the distributions of normalized WES-measured MT-CN,
separated by the number of WES-detected alternate alleles in TMBIM1 with MAF < 0.01 and
CADD score > 20 (N = 19,034).

118

Table 3.1 Associations of normalized MT-CN with disposition index and Matsuda ISI in
METSIM. Testing was done by linear regression using disposition and Matsuda ISI,
respectively, as the dependent variable. P* columns represent the P value from linear regression
with additional adjustment for fat mass. Follow-up measurements were taken at a later time
point.
Disposition index
Baseline
N

β

SE

Follow-up

P

P*

N

β

SE

P

P*

All subjects

2975 0.094 0.004 3.0×10-7

0.0004

2492 0.062 0.004

0.002

0.068

Excludes diabetic
subjects at baseline

2842 0.091 0.003 1.3×10-6

0.0007

2452 0.067 0.004

0.0009

0.041

0.023

2449 0.067 0.004

0.0009

0.042

Excludes diabetic
subjects at baseline and 2453 0.069 0.003
during follow-up

0.0007

Matsuda ISI
Baseline
N

β

SE

Follow-up

P

P*

N

β

SE

P

P*

All subjects

2975 0.192 0.005 4.3×10-26 7.3×10-17 2492 0.157 0.006 3.7×10-15 8.7×10-10

Excludes diabetic
subjects at baseline

2842 0.191 0.005 1.0×10-24 2.4×10-16 2452 0.161 0.006 1.3×10-15 3.0×10-10

Excludes diabetic
subjects at baseline and 2453 0.173 0.005 7.2×10-18 5.3×10-12 2449
during follow-up
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0.16 0.006 1.7×10-15 3.8×10-10

Table 3.2 GREML and GREML-LDMS heritability estimates for normalized MT-CN and
low-density lipoprotein (LDL) in METSIM. GREML-LDMS heritability estimates are
calculated using PCs 1-10 as fixed-effect covariates. Analyses of imputed array data exclude
samples with WGS data.
GREML
GREML-LDMS
Genotype source
N
(phenotype source)
Trait
h2
SE
h2
SE
WGS
(WGS-measured
MT-CN)
Normalized
MT-CN
Imputed array (WES-

3065

0.31

0.07

0.31

0.09

6789

0.11

0.04

0.14

0.05

WGS

3062

0.34

0.08

0.38

0.10

Imputed array

6787

0.25

0.04

0.32

0.05

measured MT-CN)
LDL
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Table 3.3 GREML heritability estimates in each cohort separately and in joint analysis. All
analyses in this table were limited to sample sets with available imputed genotype data, yielding
slightly lower sample sizes than in other tables.
WGS-measured MT-CN

Joint
Analysis

WES-measured MT-CN

N

h2

SE

N

h2

SE

WGS
genotypes

4149

0.17

0.06

3916

0.11

0.06

Imputed
genotypes

3916

0.16

0.06

17718

0.09

0.02

WGS
genotypes

3065

0.31

0.07

2974

0.20

0.08

Imputed
genotypes

2974

0.27

0.08

9791

0.11

0.03

WGS
genotypes

1084

0.20

0.22

942

0.24

0.27

Imputed
genotypes

942

0.35

0.27

7927

0.08

0.03

METSIM

FINRISK

121

Table 3.4 Mendelian randomization results after removal of high leverage post hoc outliers.
Results of Mendelian randomization test for causality of MT-CN on fasting serum insulin, after
removal of high leverage post hoc outliers (see Section 3.7.4: Inference of Causality in the
Association Between MT-CN and Insulin). These results are nearly identical to those
computed before outlier removal (Figure 3.8D), indicating that the detected signals were not
driven by outlier samples.
Dataset

n

WGS

3034

Imputed Array 6774

Meta-analysis

-

Penalty

Beta

Std. Error

P

L1

-0.019

0.013

0.1471

L2

-0.020

0.011

0.0822

L1

-0.019

0.008

0.0188

L2

-0.023

0.008

0.0045

L1

-0.019

0.007

0.0057

L2

-0.022

0.007

0.0009
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Table 3.5 MT-CN associations with insulin and fat mass in WES data. Results of EMMAX
tests of association between normalized MT-CN and both fat mass and fasting serum insulin
using WES data. Association tests were performed in all samples and also separately among
samples with and without WGS data.
All WES samples

N

Beta

SE

Samples with WGS and WES data

P

WES samples excluding WGS
samples

N

Beta

SE

P

N

Beta

SE

P

Fat mass

11577 -0.094

0.010 5.79×10-23

3016

-0.102

0.017

2.25×10-9

8561

-0.091

0.011 3.01×10-15

ln(Fasting
insulin)

9434

0.010 1.10×10-33

2689

-0.135

0.019 1.98×10-12

6745

-0.124

0.013 1.29×10-22

-0.127
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Table 3.6 Single marker association results for rs2288464 and rs9389268. Analyses of
imputed FINRISK array data were performed with covariates for FINRISK genotyping batch.
Bolded results are significant at the appropriate threshold for the given test (see Section 3.7.3).
FINRISK

rs2288464

METSIM

Joint Analysis

N

MAF

P

Beta

N

MAF

P

Beta

N

MAF

P

Beta

Imputed

7927

0.148

0.613

0.0113

9791

0.165

2.55×10-9

0.119

17718

0.158

9.77×10-7

0.075

WES

9221

0.150

0.376

0.0186

9813

0.166

6.75×10-9

0.118

19034

0.158

9.34×10-7 0.0734

WGS

1084

0.142

0.383

0.0532

3065

0.161

0.113

0.0561

4149

0.156

Imputed

7927

0.354

0.189

0.0216

9791

0.347

1.26×10-10

0.0973 17718

0.35

1.62×10-8 0.0634

WGS

1084

0.351

0.788

0.0121

3065

0.347

3.24×10-8

0.150

0.348

7.87×10-7

0.0655

0.0562

rs9389268

124

4149

0.115

Table 3.7 Replication in METSIM of published MT-CN and cell count QTLs. Results of
GWAS of METSIM using imputed genotypes (N = 9,791) for top hits in the literature for MTCN, neutrophil count, and platelet count. MT-CN loci were taken from Cai, et al.90 and Guyatt et
al.99. Neutrophil and platelet count loci were chosen as the top 5 loci in the NHGRI-EBI GWAS
Catalog for their respective traits, with some curation to ensure the loci tested were mutually
independent. All ten variants came from either trans-ethnic or European-specific GWAS reported
in reference Chen et al.202
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Trait

SNP

GRCh37
coordinates

rs445

7:92408370

rs11006126

10:60142880

Ref.

Nearest gene(s)

Cai, et
al.90

CDK6

MT-CN
rs709591

17:38175561 Guyatt
et al.99
rs12873707 13:104810437

Neutrophil
count

Platelet
count

rs25645

17:38173143

rs2814778

1:159174683

rs9131

4:74963049

rs56388170

METSIM METSIM
MAF
P value
0.0504
0.100

0.3609

CSF3, MED24,
PSMD3

0.402

1.61E-04

LOC105370340

0.061

0.5048 Not genome-wide significant in literature

CSF3

0.322

0.01712 2.5 kb away from rs709591

0.355

0.04622

7:28724374

CREB5

0.299

0.009071

rs445

7:92408370

CDK6

rs11759553

6:135422296

HBS1L

rs9861033

3:56861222

rs113608931

9:4758972

rs11066309 12:112883476
rs549888

6:33552202

0.0504
0.348

0.04842

Lead marker for MT-CN in Cai, et al.90 and
neutrophil count in Chen et al.202

2.15E-10

324 kb away from rs9389268, lead marker for MTCN in METSIM

ARHGEF3

0.339

0.2397

AL353151.2

0.301

0.3665

PTPN11

0.379

0.1081

GGNBP1

0.453

0.1007
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Not genome-wide significant in literature; MED24
is associated with neutrophil count (Chen et al.202)

0.6244

CXCL2

Chen et
al.202

Lead marker for MT-CN in Cai, et al.90 and
neutrophil count in Chen et al.202

TFAM

ACKR1, CADM3AS1
0.00056
Chen et
al.202

0.04842

Notes

Table 3.8 Gene-based rare variant association results for TMBIM1. TMBIM1 was the only
genome-wide significant gene in the WES rare-variant association tests of METSIM and the
whole dataset. Bolded results are significant at the appropriate threshold for the given test (see
Section 3.7.3).
FINRISK

METSIM

Joint Analysis

N

Fraction
with rare
allele

P

N

Fraction
with rare
allele

P

N

Fraction
with rare
allele

P

WES

9221

0.016

1.57×10-3

9813

0.013

1.44×10-6

19034

0.014

2.96×10-8

WGS

1084

0.028

0.489

3065

0.014

0.01

4149

0.013

0.01
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Table 3.9 Association results between blood cell count traits and MT-CN polygenic risk
score in 357,656 UK Biobank samples. β refers to the regression coefficient of MT-CN in a
linear regression of cell type onto MT-CN PRS and other covariates (see Section 3.7.3). Bolded
results are significant below a nominal α = 0.05.
All samples
No post hoc high leverage outliers
Cell Type
β
SE
P
β
SE
P
Leukocyte

-0.00856

0.00170

4.42×10-7

-

-

-

Monocyte

-0.00119

0.00170

0.482

-

-

-

Lymphocyte

-0.00250

0.00170

0.142

-

-

-

Neutrophil

-0.00954

0.00169

1.80×10-8

-0.00948

0.00169

2.17×10-8

Platelet

0.00548

0.00170

1.24×10-3

0.00548

0.00170

1.25×10-3
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Table 3.10 Direct associations between platelet/neutrophil counts and metabolic syndrome
phenotypes in the UK Biobank. Results of direct testing of platelet and neutrophil counts
against metabolic syndrome phenotypes chosen based on marginally significant associations for
MT-CN without adjustment for cell counts. Testing was done in the UK Biobank (N = 357,656)
using linear regression of traits onto cell counts conditional on the same covariates as the MTCN analyses (see Section 3.7.3). The bottom two rows show the results after removal of highresidual, high-leverage outliers as determined by Cook’s distance.
Fat Mass
Beta
Platelet count

SE

HDL
P

0.044 0.002 6.01×10-144

Beta

SE

Total Triglycerides
P

-0.019 0.002 1.36×10-26

Neutrophil count 0.139 0.002 <2.22×10-308 -0.142 0.002 <2.22×10-308
Platelet count
(no post-hoc
0.044 0.002 5.58×10-144 -0.019 0.002 1.19×10-26
outliers)
Neutrophil count
(no post-hoc
0.139 0.002 <2.22×10-308 -0.142 0.002 <2.22×10-308
outliers)
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Beta

SE

P

0.088 0.002 <2.22×10-308

0.179 0.002 <2.22×10-308

0.088 0.002 <2.22×10-308

0.179 0.002 <2.22×10-308

Table 3.11 Association results between metabolic syndrome traits and MT-CN polygenic
risk score in 357,656 UK Biobank samples. β refers to the regression coefficient of MT-CN in
a linear regression of cell type onto MT-CN PRS and other covariates (see Section 3.7.3). Bolded
results are significant below a nominal α = 0.05. The weight phenotype tested was that which
was measured at the time of impedance measurement.
Without platelet and neutrophil
With platelet and neutrophil
adjustment
adjustment
Trait
β

SE

P

β

SE

P

Type 2 Diabetes

-0.1681

0.0826

0.0419

-0.1467

0.0844

0.0823

BMI

-0.0372

0.0175

0.0331

-0.0233

0.0175

0.1836

Fat Mass

-0.0452

0.0176

0.0100

-0.0318

0.0177

0.0716

C-Reactive Protein

-0.0015

0.0178

0.9305

0.0206

0.0171

0.2291

HDL

0.0573

0.0187

0.0021

0.0416

0.0187

0.0262

Total Triglycerides

-0.0500

0.0176

0.0046

-0.0330

0.0175

0.0603

Weight

-0.0359

0.0176

0.0414

-0.0218

0.0178

0.2189
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Table 3.12 Associations in the UK Biobank between cell counts and loci mapped to MT-CN
in Finnish data. Association tests in the UK Biobank (N = 357,656) of cell counts against
common-variant and gene-based rare-variant MT-CN associations found in Finnish GWAS.
Single marker association statistics are calculated by linear regression, while TMBIM1 P values
are calculated by SKAT-O.
rs2288464

rs9389268

TMBIM1

Cell type
Beta

SE

P

Beta

SE

P

P

Leukocyte

0.00921

0.00406

0.023

-0.0471

0.0027

4.85×10-66

0.784

Monocyte

0.00670

0.00406

0.099

-0.0331

0.0027

2.18×10-33

0.331

Lymphocyte

0.00525

0.00407

0.197

-0.0372

0.0028

1.65×10-41

1

Neutrophil

0.00703

0.00405

0.083

-0.0363

0.0027

5.66×10-40

0.274

Platelet

0.00714

0.00406

0.079

0.1109

0.0027 <2.22×10-308
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0.082

Chapter 4: Conclusions and Future
Directions
4.1 Restatement of Aims
❏ Aim 1 (Chapter 2): Develop, implement, and evaluate a method for in silico
prediction of structural variant pathogenicity
❏ Aim 2 (Chapter 3): Interrogate the genetics of peripheral blood mitochondrial DNA
copy number (MT-CN) and its relationship to metabolic syndrome
❏ Aim 2a: Investigate the germline genetic determinants of peripheral blood
MT-CN in Finns
❏ Aim 2b: Assess the evidence for a causal relationship between MT-CN and
fasting serum insulin in Finns
❏ Aim 2c: Utilize UK Biobank data to replicate and interpret the association
between MT-CN and metabolic syndrome

4.2 Aim 1
Aim 1, discussed in Chapter 2, led to the release of SVScore, the first tool to quantitatively
assess SV pathogenicity in silico. While the strategy used in SVScore - aggregating per-base
scores in relevant intervals chosen based on SV type and transcript annotations - is rather
methodologically simple, it is quite effective. High scoring SVs showed signatures of purifying
selection (Figure 2.3), scores were more informative than SV length (Figure 2.3 and Figure
2.7), and known pathogenic variants from ClinGen were virtually all assigned high scores
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(Figure 2.8). Furthermore, application of SVScore to a set of real SVs resulted in interesting
biological findings such as noncoding SVs under negative selection and similar levels of
selection among high-scoring deletions and duplications (Figure 2.3). SVScore is implemented
as a lightweight VCF annotation tool and is freely available online
(https://github.com/lganel/SVScore).
Since the 2017 publication of the manuscript in Section 2.5, many new techniques have
been developed to address the pathogenicity prediction problem for SVs218–223. On the whole,
these methods are more methodologically complex than SVScore, with many incorporating
machine learning to assess SV impact. This is a natural progression for the field given the power
of machine learning and the promise it has shown in the SNP impact prediction space. However,
machine learning is an extremely complex class of methods in which many different strategies
can be employed; further work should continue to explore these possibilities to search for
improved pathogenicity prediction.

4.3 Aim 2
Aim 2 was a more ambitious undertaking than Aim 1, seeking to understand the biology of the
association between MT-CN and metS(Figure 3.3 and Table 3.1). This was done first by
understanding the genetics of MT-CN through heritability (Table 3.3) and GWAS analyses
(Figure 3.12 and Figure 3.14). This led to a heritability estimate (31% with 7% SE) comparable
to that of LDL (Table 3.2), which is consistent with values found in the literature. Also, one
reliable common variant association was identified at rs9389268 as well as one novel risk gene,
TMIBIM1, which was identified through RVAS.
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Next, a causal inference experiment was undertaken to search for causality in the
relationship between MT-CN and fasting serum insulin. A penalized regression based MR
pipeline was developed to build a genetic instrument from a large number of genotypes while
enforcing the MR assumptions using phenotype data (Figure 3.8). This strategy was
implemented and applied to FinMetSeq data, resulting in statistically significant evidence of a
causal role for MT-CN in this relationship (Figure 3.8D).
Finally, the genetic instrument built in Finns was applied as a PRS in approximately
350,000 individuals of British ancestry in the UK Biobank. In this dataset, the associations of
MT-CN with rs9389268 (Table 3.12) and metS (Table 3.11) were replicated. Also, associations
between MT-CN and blood composition were discovered and found to mediate the association
with metS (Table 3.11), suggesting that MT-CN acts as a proxy for neutrophil and platelet
counts in its link to metS. This agrees with previous studies showing that inflammation plays a
role in this disorder.
While the associations between MT-CN and both metS and CVD have long been studied,
most of this work has been limited in power and methodology. As a result, the literature on the
subject is often contradictory and difficult to interpret, creating a need for a definitive study of
these associations. The work described in Chapter 3 improves on prior published work with its
large sample size, rich phenotype data set, use of a highly accurate MT-CN quantification
method, and novel MR method. This study replicated some previously detected MT-CN QTLs
and identified other, novel associated loci.
Further work on MT-CN should seek to disentangle the effects of mitochondrial
abundance and cell type composition. The data used in Chapter 3 were limited by the availability
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of some crucial phenotypic information, as MT-CN and blood cell type composition were not
both measured in any single data set. One avenue of future investigation could measure MT-CN
in the UK Biobank using microarray intensity or newly released WES data from 200,000
individuals. While these measurement methods are noisy relative to WGS, the method used in
Chapter 3 was also limited by the application of a PRS in a population different from that in
which it was built. As a result, direct measurement in the UK Biobank may prove to be more
fruitful. Furthermore, the UK Biobank plans to release WGS data in the future; when this
happens, more accurate measurements can be made. Direct measurement of MT-CN in the UK
Biobank is advantageous because this data set also has blood cell count measurements, and thus
has the potential to be useful in understanding the extent to which blood cell composition itself
contributes to metS via MT-CN.
Future work should also focus on creating a better understanding of the genetic loci
responsible for MT-CN, ideally separating these loci by whether they impact mitochondrial
abundance or blood composition. Several previously identified MT-CN loci replicated in Chapter
3, but several others did not. More work is required to understand whether these were false
positives in prior studies, false negatives in the current work, or neither (e.g. population-specific
QTLs). TMBIM1 is a particular example of this: rare variants in this gene were not associated
with blood cell counts in the UK Biobank, raising the question of whether this gene is truly
associated with MT-CN in Finns, and if so, whether it modulates mitochondrial abundance per
cell. Furthermore, the direction of effect of presumably loss-of-function TMBIM1 variants (i.e.
those with high CADD scores and low MAF) in the current study suggests that it is a metS risk
gene, while prior work found it to be protective against NAFLD in model organisms. This may
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simply be a result of differing biology between species, but further analysis is required to address
this question.

4.4 Parting Thoughts
Computational analyses are only as powerful as the data under study. In particular, the
machine learning methods discussed in Section 4.2 depend heavily on the quality of their
training data. These methods will likely require identification of large numbers of pathogenic and
benign variants as well as accurate classification as such. Genomic annotations are also crucial to
these methods, and the proliferation of various -omics technologies mean that our understanding
of the biology of the human genome is constantly improving. Cultivation of this knowledge will
undoubtedly contribute to the success of these methods.
Another issue is the relative ethnic homogeneity of the data currently available; as
scientists, we have a social responsibility to analyze ethnically diverse samples to ensure our
findings are applicable to varied populations. Moreover, analysis of alleles specific to
understudied ethnic groups is likely to yield novel insights into the biology of the human genome
that can benefit everyone. Thus, analysis of diverse human genomes is both a moral obligation
and a strategic choice, and I am encouraged to see large efforts to move the field in this direction.
Many current analyses are limited by sample size due to the multiple testing burden
inherent in analyzing a genome of 3 billion base pairs. This makes it difficult to detect statistical
signals of modest size, leaving questions about the genetic architecture of common traits and
diseases unanswered. Furthermore, the ever-increasing accessibility of WGS means that data are
perpetually becoming available through large-scale WGS data sharing initiatives45,65 .
Simultaneously, advanced computational methods continue to develop, e.g. those using graph136

based reference genomes, which are a natural choice for multi-ethnic studies. With these
constant improvements, investigators may find previously unfeasible study designs becoming
possible. Paired with newer, more efficient methods, the current trend toward increased data
sharing and accessibility is an encouraging sign for enabling these types of large-scale analyses.
A new generation of cohort studies is currently underway, including continued
sequencing by the UK Biobank as well as the National Institutes of Health’s All of Us program
(https://allofus.nih.gov/), which aims to collect genetic data from over a million Americans of
diverse backgrounds. It is my hope that these newer projects continue to hold true to the
principles of data sharing in order to allow the broader scientific community to mine these rich
resources for the knowledge they hold. This is not a simple task due both to logistics and the
ethical imperative of ensuring patient consents are honored. However, the result of solving these
problems is a more democratized and productive scientific community that will lead to better
biological understanding and public health.
Ultimately, the goals of genomic research are twofold: furthering basic scientific
knowledge and clinical application. Much of the work in this field has been rightly focused on
the former as a solid biological foundation is necessary before applying these technologies
widely to patients. However, I am encouraged by the high quality translational work already
taking place, as our technology and scientific understanding are already mature enough to make
a positive impact on patients. I hope to see this work expand in the future toward a healthcare
system that incorporates genetic data ethically and efficiently to improve patient outcomes.
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